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ABSTRACT 
MAN LUO: Cheminformatics Modeling of Diverse and Disparate Biological Data and the 
Use of Models to Discover Novel Bioactive Molecules 
(Under the direction of Dr. Alexander Tropsha) 
 
Ligand-based drug design is a popular and efficient computational approach to 
facilitate the drug discovery process. Current approaches mainly focus on optimizing the 
computational algorithms to improve the efficiency or accuracy of virtual screening; however, 
the success of ligand-based drug design relies not only on the effectiveness and robustness of 
the underlying algorithms, but much more importantly, on the quality of the data for model 
building. Although numerous chemical probe databases have emerged recently
1-4
, few 
evaluation of data quality and reliability have been performed. 
Building upon our lab‟s experience in Quantitative Structure-Activity Relationship 
(QSAR) method and methods developed in the field of cheminformatics, this dissertation 
focuses on: 1) Investigation and comparison of the predictive power of QSAR methods with 
other ligand-based drug discovery approaches, such as Similarity Ensemble Approach (SEA) 
and Prediction of Activity Spectra for Substances (PASS); 2) Using QSAR methods to 
validate the consistency and reliability of biomedical data in disparate data sources. 3) 
Developing a novel, rigorous and dataset-specific QSAR workflow for the application on 
multiple therapeutic targets in order to identify diverse hits with high potency in practical 
virtual screening projects. These works succeed in thoroughly investigating the current 
approaches for ligand-based drug discovery, exploring the consistency and quality of major 
iv 
 
annotated cheminformatics databases, and identifying many pharmaceutically important 
ligands. The success of our studies harshly challenges some popular multi-target profile 
prediction methods and contributes to the development of cheminformatics by emphasizing 
the importance of determining trustworthy data sources. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background 
Drug design is the inventive process of finding new medications based on the 
knowledge of the biological target or a series of pharmacological agents that modulate it. 
Other than the classical medicinal chemistry of Structure-Activity Relationship (SAR) 
analysis, the Computer-Assisted Drug Design (CADD) techniques have become more and 
more popular recently. They have been proven to greatly improve the efficiency of the drug 
discovery process, and save a huge amount of money at the same time. For example, the 
introduction of rational drug design with the aid of computational works led to the discovery 
of Gleevec to inhibit bcr-abl kinase for the treatment of Chronic Myelogenous Leukemia 
(CML)
5
. The combination of computational chemistry concepts, robust software, and high-
end computer hardware are used to assist the medicinal chemists identifying or designing 
ligands that are more likely to interact with the biological target of interest. CADD methods 
can be categorized as ligand-based and structure-based drug design based on the availability 
of crystal structures for the target of interest. If the three-dimensional (3D) structure of the 
target protein is available, structure-based drug design approaches could be used, which 
basically use active and/or binding site identification methods, and docking methods along 
with different scoring functions to rank screening compounds‟ structures as well as their 
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poses. Those compounds with the highest ranks would be proposed to be computational hits, 
and then rendered for experimental tests, if applicable. If the structure of the target protein is 
not known, which is a more common case; ligand-based drug design methods are used. The 
methodologies are based solely on the structure and activity data for series of ligands to a 
biological target of interest; the protein structure is not used. In this case, all chemical 
structures are represented by numeric characteristics called molecular descriptors. The 
generated descriptor matrix consisting of m rows (each row represents a compound) and n 
columns (each column represents a descriptor) will then be analyzed by diverse data analysis 
approaches, with the aim of better understanding the underlying nature of current data, and 
making predictions for new molecules. It can also be said that each molecule is represented 
by a point in the multidimensional descriptor space. In this chapter, a brief introduction of 
ligand-based drug discovery and various popular data analysis methods in cheminformatics 
research will be introduced. Then, the limitations for existing concepts and methodologies 
will be covered, leading to the topics that this dissertation will attempt to address.   
1.2 Introduction to Ligand-based Drug Discovery 
Ligand-based drug design relies on experimental binding data to a target of interest 
for a set of small molecules. By analyzing these molecules using various 3D data analysis 
approaches, a pharmacophore model can be derived, which defines the minimum necessary 
structural characteristics a molecule must possess in order to bind to the receptor. One of the 
keys to the success of finding novel ligands is the underlying data analysis approaches in 
cheminformatics.  
Intelligent data analysis with subsequent database mining is a common and efficient 
approach for the discovery of lead compounds. Usually, the input data for data analysis is a 
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descriptor matrix (see above). Various descriptors can be calculated using available software, 
such as Dragon
6
, Molconn-Z
7
, MOE
8
, MACCS keys
9
, eTc. Different physicochemical 
properties (calculated or measured), invariants of molecular graphs, indicators of 
presence/absence of specific chemical groups in a molecule and counts of different fragments, 
eTc. can serve as descriptors.  Data analysis approaches can be divided into supervised 
learning and unsupervised learning. In supervised learning, biological activities or properties 
of molecules (Y) are used, and the main goal is building models capable of accurate 
prediction of activities or properties of compounds not included in the modeling dataset. In 
unsupervised learning, activity data (Y) are not used. The main goals of unsupervised 
learning are establishing hidden data structure and finding general properties of the dataset, 
like how many well-distinguished clusters of compounds exist, obtaining principal 
components accounting for most (for example, 95% of the valiance), factor analysis, eTc. 
(Figure 1.1). The Quantitative Structure-Activity/Property Relationship (QSAR/QSPR) 
analysis includes various supervised (or semi-supervised) learning approaches as used in 
cheminformatics
10
. The main goal of QSAR/QSPR analysis is building models capable of 
accurate prediction of biological activities or properties of compounds. Descriptor matrix 
(see above) and activities or properties of a series of compounds are used as input variables. 
The QSAR puzzle can be mathematically described as deriving the equation:  
Predicted Activity = f (descriptors)                                           (1) 
in which the error of prediction is minimized in some way. Different functions in (1) 
correspond to different multivariate statistical modeling techniques used to generate these 
predictive models. Each method tries to tune its function parameters to minimize the error of 
prediction for the training set. Then the models are validated using test set compounds, not 
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used in building models
11, 12
. If the biological endpoints belong to only a small number (2-4) 
of classes, for example, protein binders or non-binders, the models‟ predictive accuracy is the 
correct classification rate (CCR), which is the (weighted) average of correct classification 
rates of each class or category (in case of two classes they are called sensitivity and 
specificity). CCR is optimized for the training set during model building. For an acceptable 
model, the CCR should not be lower than some predefined value (for example, for a binary 
dataset, it should not be lower than 0.7, eTc.) Usually, sensitivity and specificity values are 
also reported to evaluate the performance of models for each class.  If the endpoints are 
continuous, cross-validation q
2
 is usually maximized during model building, and the 
following statistics for the test set are also used to estimate the predictive power of the 
model: R
2
, R0
2
, MSE, eTc
13
. QSAR methods can be divided into linear (e.g. Partial Linear 
Squares and Multiple Linear Regression) and non-linear methods (e.g. k-Nearest Neighbor, 
Random Forest). On the other hand, unsupervised learning approaches only use the 
compounds‟ structural information, and no model training procedure is involved. Figure 1.1 
shows two popular unsupervised learning techniques, hierarchical clustering and principal 
component analysis, to analyze and better understand the characteristics of current data. 
Predictions can also be made by unsupervised learning, which predict the biological profile 
(binder or non-binder) of a new chemical entity to a given target based on the structural 
similarity as compared to known ligands. 
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Figure 1.1. Popular data analysis approaches in cheminformatics. Various types of 
descriptors are available for the representation of compounds‟ chemical structures. The 
numeric matrix after the descriptor calculation will then be analyzed by different machine 
learning methods, which are categorized by either supervised learning or unsupervised 
learning. Supervised learning methods try to find the relationship between the descriptors of 
chemical compounds with their biological activities (Ys). If the endpoints of Y are 
categorical, classification modeling methods will be applied, with the prediction results 
represented by the confusion matrix. If Ys are continuous, regression models will be used. 
Unsupervised learning methods try to find the relationships between those chemical 
compounds themselves, without considering the Ys.  
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1.3 Current Limitations for Existing Methodologies 
 The Cheminformatics research has been developing rapidly in recent decades, and 
numerous data analysis methods have emerged in the forms of both academic freeware and 
commercial software packages. It is ideal that models are available for all targets of interest, 
pharmaceutically relevant receptors and biologically meaningful proteins, so that systems-
level investigations can become realistic with the efficient multi-profile predictions. However, 
calculation speed is not all that we should care about; prediction accuracy should always be 
the most important feature we care about. Some web-based cheminformatics prediction 
servers, such as Similarity Ensemble Approach
14
 (SEA), become very popular recently, 
which only apply the simple similarity search technique for the purpose of efficient multi-
profile predictions. The fast feedback and friendly simple interface attract many users, 
especially scientists not in the cheminformatics field. In this dissertation, diverse data 
analysis techniques will be investigated and comprehensively compared. 
Successful ligand-based drug discovery projects involve much more than simply 
applying different data analysis approaches in readily available web-based servers or 
software packages. Observations suggest that most efforts were made to optimize the 
computational algorithms in the purpose of improving the efficiency and/or accuracy of 
virtual screening
15
; however, the success of the methods relied not only on the effectiveness 
and robustness of the underlying algorithms, but much more importantly, on the quality of 
the data for model building
16
. Although numerous chemical probe databases have emerged 
recently, such as PubChem
1
, ChEMBL
2
, WOMBAT
3
, , seldom evaluation of data quality and 
reliability was performed. 
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 In addition, since many successful stories
11, 12, 17, 18
 proved the robustness and 
predicting accuracy of Quantitative Structure-Activity Relationships (QSAR) approaches, 
many researchers simply apply the conventional QSAR (Multiple Linear Regression) and the 
following virtual screening workflow, without taking consideration of the dataset they 
currently have. In this dissertation, we propose that instead of carrying the same QSAR 
workflow universally, dataset-specific QSAR approach should be used, which adjusts the 
procedures based on the special features of existing data or the different objectives one wants 
to achieve. For example, we will try to show that combining supervised learning of QSAR 
with unsupervised learning techniques (hierarchical clustering) could successfully address 
the problem of building models on a dataset with highly diverse compound structures. 
 
1.4 Overview of Chapter 2 
In this chapter, various state-of-the-art data analysis tools in cheminformatics for 
predicting compounds‟ biological properties will be briefly introduced. For supervised 
statistical learning, QSAR methods will be discussed, encompassing different algorithms 
such as k-Nearest Neighbors (kNN), Random Forest (RF) and Support Vector Machine 
(SVM). The concept of applicability domains and external validation tests will also be 
covered. For other popular cheminformatics techniques, the underlying algorithms for two 
multi-profile prediction approaches, the Similarity Ensemble Search (SEA) and Prediction of 
Activity Spectra for Substances‟ (PASS) will be introduced. These methods will be 
comprehensively compared by 7 cases of biological receptors. We will demonstrate that the 
SEA method shows the worst records for both the internal retrieval rate and external 
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prediction accuracy for all tested datasets; PASS have a much higher prediction accuracy; 
and QSAR models are the best among all. 
1.5 Overview of Chapter 3 
 In this chapter, we first present and investigate several popular cheminformatics 
databases, including PubChem, PDSP and WOMBAT, and then apply QSAR approach to 
validate the consistency of data deposition in these databases to identify low signal-to-noise 
ratio data source. QSAR models for the same biological targets are generated separately for 
data obtained from different sources, and used for inter-database cross-validations. 
Computationally suggested false positive compounds are further tested experimentally to 
support our predictions. Results show that in the investigated cases both PDSP and 
WOMBAT datasets are trustworthy data sources, but the PubChem dataset is not. The nine 
PubChem 5-HT1A binders are identified to be false positives by the inter-database CV, and 
are further validated in the experimental tests, confirming our model predictions to be 100% 
accurate. These studies will contribute to the development of cheminformatics by suggesting 
an ever-increasing role of determining trustworthy data sources before model building. 
1.6 Overview of Chapter 4 
 Antibiotic resistance is an escalating problem requiring the discovery of novel 
antibiotic classes acting on nonclassical cellular targets. Targeting the protein involved in 
DNA repair, RecA, offers possible attractive solution, because it directly combat the 
development and transmission of antibiotic resistance and thus makes antibiotics more 
effective. In this chapter, we firstly developed QSAR models for the first version dataset 
containing 53 RecA inhibitors and 3,435 non-inhibitors, and identified those RecA non-
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inhibitors with false labeling. The dataset is then curated and more tested compounds are 
included, making the second version dataset contains 145 RecA inhibitors and 26,288 non-
inhibitors. Due to the high structural diversity this new dataset presents, we developed 
combinatorial QSAR models using the novel “Divide-and-Conquer” approach, which 
involves hierarchical clustering prior to QSAR modeling. The variable selection kNN, RF 
and SVM will be employed for model building within each group, and the two groups that 
render the best model statistics (group 1 and 2) are used in virtual screening. Computational 
hits are tested experimentally, revealing novel and potent RecA inhibitors for further drug 
discovery. 
1.7 Overview of Chapter 5 
The 5-Hydroxy Tryptamine receptor subtype 1A (5-HT1A) has been an attractive 
target to treat mood disorders such as anxiety and depression. In this chapter, we develop 
classification combinatorial QSAR models for 5-HT1A receptor using data retrieved from 
the PDSP Ki database, the trustworthy data source that has already been confirmed in 
Chapter 3. We employ a rigorous model development workflow, including extensive internal 
and external validation, and apply them for consensus prediction for the purpose of mining 
chemical libraries with different characteristics: drug-like libraries from the World Drug 
Index and Prestwick, GPCR-targeted libraries from TimTec and ASINEX, and diversity 
libraries from TimTec and ASINEX. Results shows that the computational hits from a drug-
like library share the most similar structures with 5-HT1A binders already known, while hits 
from GPCR-targeted library are much more structurally diverse, and hits from a diversity 
library are the most diverse ones. Five hits from each library are further tested in radioligand 
binding assays, and in total of nine novel structures of 5-HT1A binders are discovered. 
10 
 
1.8 Overview of Chapter 6 
In this chapter, we present a summary of all above studies. It not only identifies 
pharmaceutically important hits for drug discovery, but also encompasses a thorough 
investigation of the current approaches for multi-target profile predictions, but will also shed 
light on the consistency and quality of major annotated chemogenomics databases. These 
studies will contribute to the development of cheminformatics and influence the process of 
drug discovery by suggesting an ever increasing role of QSAR modeling and the importance 
of determining trustworthy data sources. 
 
  
CHAPTER 2 
METHODS 
 
2.1 Introduction 
Various cheminformatics tools, such as QSAR modeling, are fundamentally based on 
the similarity principle implying that compounds with similar chemical structures have 
similar biological properties. Consequently one can predict the biological target property of a 
molecule from that of chemically similar compounds for which the property is already 
known. However, QSAR modeling builds quantitative predictive models based on a 
similarity matrix using various machine learning techniques, while SEA as well as other 
generic multi-target techniques simply applies similarity search comparisons; herein, the 
predictive performance of QSAR methods will be compared with that of the approach 
predicting generic multi-target profiles, namely „Similarity Ensemble Approach‟ (SEA)14 and 
„Prediction of Activity Spectra for Substances‟ (PASS)19. The ouTcome of this chapter (a 
compendium of generated models) will serve as a reliable tool for the virtual biological 
profiling of small molecules in Chapter 3, 4 and 5. In this chapter, the background 
information about QSAR as well as other generic multi-target cheminformatic techniques 
will be briefly introduced first, and then a comparison of methods will be performed on 
various datasets, followed by assessment results and discussion. 
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2.2 Background Information of QSAR 
QSAR, which stands for Quantitative Structure-Activity Relationship, is a statistic 
learning methodology of searching, optimizing and validating the best possible mathematic 
equations that quantitatively correlate a set of chemical structures with their experimentally 
defined biological or chemical activities. The chief hypothesis of the QSAR approach is that 
if an implicit structure-activity relationship exists for a given data set, it can be formally 
manifested via a variety of QSAR models obtained with different descriptors and 
optimization protocols. 
QSAR's most general mathematical form is:  
Activity = f (physiochemical properties and/or structural properties) 
Once established, QSAR models can be then used to predict the biological responses of other 
similar chemical structures. 
 
2.3 Descriptors Used 
2.3.1 Dragon descriptors 
A set of 843 theoretical molecular descriptors was computed using DRAGON 
software
6
. The descriptors were generated from the SMILES strings available for each 
compound. The descriptors include the following types: 0D constitutional (atom and group 
counts); 1D functional groups; 1D atom centered fragments; 2D topological descriptors; 2D 
walk and path counts; 2D autocorrelations; 2D connectivity indices; 2D information indices; 
2D topological charge indices; 2D Eigenvalue-based indices; 2D edge adjacency indices; 2D 
Burden eigenvalues and molecular properties. In studies in this dissertation, no 3D 
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descriptors were used, and all descriptors were calculated with hydrogens, and were range-
scaled. Descriptors which had the same value for all compounds or had less than 5% variance 
were deleted. If two descriptors were at least 98% correlated one of them was deleted. The 
definition of these descriptors and related literature references are reported elsewhere
6
. 
2.3.2 MACCS key fragment-based descriptors 
For the feature list version of the MACCS Structural Keys used in our studies, each 
feature indicates the presence of one of the 166 public MDL MACCS structural keys 
(fragments) computed from the molecular graph. The fingerprint is represented as a sparse 
list of keys present in the molecule, as shown in Figure 2.1. 
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Figure 2.1. Depiction of MACCS key fragment-based descriptors 
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2.4 QSAR Methodology 
Computer-aided drug design laboratories
20-24
, including ours, has concentrated on the 
development and application of fast, nonlinear, automated variable selection algorithms for 
QSAR modeling. These methods include but not limited to Genetic Algorithms-Partial Least 
Squares
11
 (GA-PLS), k-Nearest Neighbor
25
 (kNN), Random Forest (RF)
26
, and Support 
Vector Machine (SVM)
27
. It has been demonstrated that such methods could efficiently 
improve QSAR models, compared with those without variable selection
25
. An important 
aspect of these methods is, as we have shown earlier
11, 25, 28
, that they can be used for 
combinatorial library design and database mining. Most of the above techniques can deal 
with both binary and continuous endpoints, but for the continuous ones, a large variance from 
experiment tests contributes a heavy negative effect on the predictive model building process. 
Therefore, in this dissertation, binary response variables are exclusively considered, and all 
of the descriptions below are based on the results derived from methods used only in binary 
classification QSAR. 
Another recent trend in QSAR modeling, which is especially emphasized in our 
studies, is model validation. It is known that the increase in the number of independent 
variables leads to a higher probability of chance correlation between predicted and observed 
activities
29
; Therefore, model validation is one of the most important aspects of the analysis. 
To validate a QSAR model, the majority of authors apply the leave-one-out (LOO) or leave-
some-out (LSO) cross-validation procedure. The ouTcome from this procedure is a cross-
validated Correct Correlation Rate (CCR). For a balanced dataset (dataset that has 
comparable numbers of binders and non-binders), the CCR is defined as
30
: 
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where 
1
totalN  and 2
totalN  are the number of binders and non-binders in the dataset, 1
corrN  and 
2
corrN  are the number of known binders predicted as binders (true positives) and the number 
of non-binders predicted as non-binders (true negatives). For imbalanced (biased) dataset, 
another alternative CCR to Equation 2 could include weights (W1 and W2) for each class, 
with smaller weights assigned for larger classes. 
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The statistical significance of the training and test set models is characterized by the 
LOO-CV CCRtrain and predictive CCRtest, respectively. In summary, the variable selection 
kNN classification method generates stochastic models that usually finalized with values 
equal to (or close to) the global minimum, with the highest (or nearly highest) value of CCR 
characterized by the optimal k value, the number of nearest neighbors, and a subset of 
selected descriptors. 
The summations in Equation 3 are performed over all compounds, which are used to 
build a model (training set). Many authors consider high CCRtest
 
(for instance, CCRtest > 0.7) 
as an indicator or even as the ultimate proof of the high predictive power of a QSAR model
31
. 
They do not test the models for their ability to predict the activity of compounds of an 
external test set (i.e., compounds), which have not been used in the QSAR model 
development
32-36
. Some authors validate their models using only one or two compounds that 
were not used in model development
37, 38
. 
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Our laboratory has recently demonstrated
17, 39
 that various commonly accepted 
statistical characteristics of QSAR models derived from a training set are insufficient to 
establish and estimate the predictive power of the models. As was suggested in several recent 
publications
40-43
, including our own work
17, 39
, the only way to ensure the high predictive 
power of a QSAR model is to demonstrate a significant correlation between predicted and 
observed activities of compounds for an external validation (test) set, which is not employed 
in model development. We argue that special approaches should be used to select a training 
set to ensure the highest significance and predictive power of QSAR models
44, 45
. Our 
approach to QSAR modeling does involve extensive validation as discussed below in 
Chapter 3, 4, and 5. 
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Figure 2.2. The workflow of QSAR model building, validation and virtual screening. 
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2.4.1 K-Nearest Neighbors (kNN) 
2.4.1.1 kNN Classification Methodology 
The kNN classification QSAR method 
46, 47
 is based on the idea that the class that a 
compound belongs to can be defined by the class membership of its nearest neighbors (i.e., 
most similar compounds) taking into account weighted similarities between a compound and 
its nearest neighbors. Since our implementation of kNN approach includes simulated 
annealing (SA) based variable selection
25
 as a stochastic optimization algorithm, the 
similarity is evaluated using only a subset of all descriptors, and is characterized by weighted 
Euclidean distance between compounds in multidimensional descriptor space. Thus, the class 
membership of compound i can be predicted from the following equation: 
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and k is the number of the nearest neighbors (k = 1 to 9) of compound i, yj is the class 
membership of compound j (1 or 2) and dij is the Euclidean distance between compound i 
and its j
th
 nearest neighbors. In practice, the value of 'ˆ
iy  is rounded to either 1 or 2 to 
determine the class membership of compound i: 
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        iy
'ˆ  = round ( iyˆ )                                (5) 
The model is internally validated by leave-one-out cross-validation (LOO-CV) where each 
compound is eliminated from the training set and its class membership is predicted as the 
class the majority of its k nearest neighbors belong to. The descriptor set is optimized by 
simulated annealing approach with the Metropolis-like acceptance criterion to achieve the 
best CCRtrian value. 
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Figure 2.3. Prediction based on k-nearest neighbors. When k=3, which is demonstrated 
here, the three nearest neighbor compounds of the query compound (green circle) are 
identified. Since two of them belong to class B, and they are closer (weight heavier) to the 
query compound than the class A compound, the external compound is predicted to be class 
B.   
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2.4.1.2 Applicability Domain of kNN Models 
When developing QSAR models, each compound is represented as a point in M-
dimensional descriptor space (where M is the total number of selected descriptors); thus, the 
molecular similarity between any two molecules can be characterized by the Euclidean 
distance between their representative points. The Euclidean distance di,j between two points i 
and j (which correspond to compounds i and j) in M-dimensional space can be calculated as 
follows: 



M
k
jkikij XXd
1
2)(                                (6) 
Compounds with the smallest distance between one another are considered to have the 
highest similarity. 
Theoretically, for any compound that can be represented by its chemical or 
physiological descriptors, one should be able to predict its class membership using the 
classification kNN approach. However, if the distance between the query compound and its k 
nearest neighbors in the training set is large, then the query compound is too dissimilar to the 
training set compounds, and the prediction of its activity using the kNN approach for this 
compound could be imprecise. Therefore, a similarity threshold (or model applicability 
domain) should be introduced to avoid making predictions for compounds that differ 
substantially from the training set molecules 
48
. The similarity threshold is defined as follows: 
DT =  + Zσ                                     (7) y
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Here,  is the average Euclidean distance of the k nearest neighbors of each compound 
within the training set (where the value of k is the same as in predictive kNN QSAR models), 
σ is the standard deviation of these Euclidean distances, and Z is an arbitrary parameter to 
control the significance level. Typically, we set Z to 0.5, which places the boundary for 
deciding whether a compound is within or outside of the applicability domain at one half of 
the standard deviation. It is important to notice that increasing the value of Z would increase 
the number of compounds in the external set that are considered within the applicability 
domain but could decrease the accuracy of prediction due to inclusion of dissimilar nearest 
neighbors. 
2.4.3 Random forest (RF) 
Random forest (RF) is an ensemble classifier that consists of many decision trees and 
outputs the class that is the mode of the class's output by individual trees. The algorithm for 
inducing a random forest was developed by Leo Breiman
 
and Adele Cutler
49
. The term came 
from random decision forest that was first proposed by Tin Kam Ho of Bell Labs in 1995
50
. 
The method combines Breiman's "bagging" idea and the random selection of features, in 
order to construct a collection of decision trees with controlled variation. The selection of a 
random subset of features is an example of the random subspace method, which is a way to 
implement stochastic discrimination proposed by Eugene Kleinberg
51
.  
Each tree is constructed as follows: 1) Let the number of training cases be N, and the 
number of variables in the classifier be M; 2) The number m (much less than M) represents 
the subset of M, and the number m of input variables are used to determine the decision at a 
node of the tree; 3) Choose a training set for this tree by choosing N times with replacement 
y
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from all N available training cases (i.e. take a bootstrap sample), and use the rest of the cases 
to estimate the error of the tree, by predicting their classes; 4) For each node of the tree, 
randomly choose m variables on which to base the decision at that node, and calculate the 
best split based on these m variables in the training set; 5) Each tree is fully grown and not 
pruned
52
. 
In our studies, the R package of Random Forest (randomForest) was applied
53
, using 
default parameters. 
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Figure 2.4. Prediction based on random forest algorithms. The prediction output is the 
average results from all individual trees.   
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2.4.4 Support Vector Machines (SVM) 
Support Vector Machines (SVM) was originally developed by Vapnik
54
 as a general 
data modeling methodology where the training set error and the model complexity are 
incorporated into a special loss function and simultaneously minimized during model 
development. The importance of the prediction error versus the model complexity can be 
tuned during the optimization process, in order to generate models with reasonable 
complexity and avoid overfitting. SVM was later extended to afford the development of 
SVM regression models for datasets with non-integer variables. 
We have implemented SVM for QSAR modeling as described earlier
55
. In brief, 
given a training set of pairs ( , ),   1...i ix y i m , where ix  is an array of descriptors of each 
compound and iy  is its biological activity (e.g., group label as binder or nonbinder), the 
sought correlation between structure and activity can be represented as ( )i iy f x . For 
simplicity, we define ( )if x  as a linear function: 
( ) ,i i if x w x b        (8)  
where wi is the coefficient vector of the linear function and b is the bias. A major goal of the 
SVM regression algorithm is to minimize the loss function, which is a combination of 
prediction error defined by i  and the magnitude of the coefficient C in the following 
equation: 
min 12
m
ii
w
loss C 

        (9) 
with the constraint: 
( ( ) )i i iy w x b                  (10) 
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Here the training vectors 
ix  are mapped onto a high dimensional space by a kernel function 
 . In the end, SVM regression is expected to find a linear correlation between the actual 
activity and this high dimensional space ( )ix . For this study, we have implemented a linear 
kernel. C is a penalty parameter of the error term that controls the weight between two terms 
in the SVM optimization process. 
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Figure 2.5. Support Vection Machine (SVM) with maximum seperation. 
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2.4.5 Robustness of QSAR models 
The Y-randomization test is widely used to ensure model robustness 
56
. It includes 
rebuilding the training set models using randomized activities (Y-vector) of the training set 
and comparing the resulting model statistics with that of the original test set. It is expected 
that models built with randomized activities should have significantly lower CCR values for 
both the training and test sets. In the model-building process, it is possible that sometimes, 
though infrequently, high CCR values may be obtained due to a chance correlation or 
structural redundancy of the training set. If QSAR models obtained in the Y-randomization 
test have relatively high LOO-CV CCRtrain as well as predictive CCRtest, it implies that 
acceptable QSAR models cannot be obtained for the given dataset by the current modeling 
method. Herein, we applied the one-tail hypothesis to confirm the robustness of our QSAR 
models. 
In this approach, two alternative hypotheses are formulated: (1) for H0, h=μ; (2) for 
H1, h>μ, where μ is the average value of CCRtrain for random models and h is that for the 
actual models. The null hypothesis (H0) states that the QSAR models for the actual dataset 
are not significantly better than random models, while the H1 hypothesis assumes the 
opposite, suggesting that the actual models are significantly better than the random models. 
Hypothesis rejection is based on a standard one-tail test, which involves the following three 
steps: (1) Determine the average value of CCRtrain (μ) and its standard deviation (σ) for 
random models; (2) Calculate the Z score that corresponds to the average value of CCRtrain (h) 
for the actual models using the following equation: 
Z = (h- μ)/σ               (12) 
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(3) Compare this Z score with the tabular critical values of Zc at different levels of 
significance (α)60 to determine the level at which H0 should be rejected. If the Z score is 
higher than tabular values of Zc, one concludes that at the level of significance that 
corresponds to that Zc, H0 should be rejected while H1 should be accepted. In this study, the 
Y-Randomization test was applied to all data sets considered in this study, and the test was 
repeated twice in each case. 
2.5 Background Information of Generic Multi-target Techniques 
2.5.1 Similarity Ensemble Search (SEA) 
Similarity Ensemble Approach (SEA) is a recently developed cheminformatics tool 
used for predicting protein similarities as well as ligand‟s off-target binding57.  It compares 
protein targets by the similarity of the ligands that bind to them, with prediction confidence 
expressed as expectation values, adapting the BLAST algorithms. For example, two subsets 
of the ligands in MDL Drug Data Report (MDDR) database are compared, which are 
annotated according to the receptor they modulate. Each ligand in each set was compared to 
each ligand in the other set. Tanimoto coefficients (Tc) of chemical similarity were 
calculated for each pair of ligands. Most ligand pairs with insubstantial similarity have the Tc 
range in 0.2 to 0.3. The compound pairs with Tc values over 0.57 are considered to be 
different. The raw similarity score of the set, which is the sum of ligand pair Tc over all pairs 
with Tc ≥ 0.57, is calculated and the significance of it can be shown after correction for 
random expectation. Using a statistical model, any raw score for ligand sets of any size can 
be compared by Z-scores and expectation values (Figure 2.6). Therefore, protein comparison 
is realized by comparing the ligand sets that bind to them. Moreover, the prediction of 
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whether a ligand will bind to a specific target or not can be performed by comparing the 
ligand‟s structural similarity among the ligand set of the target. They claimed a confidence 
prediction is made when the expectation value ≤ 10-10.  
In their paper published in Nature Biotechnology
14
, when screened internally against 
all MDDR molecular targets, SEA can recapitulate 19% of the off-targets binding reported in 
WOMBAT but missing from the MDDR. For new drug-target predictions, SEA successfully 
predicted the drug of N,N-dimethyltryptamine (DMT) strongly binds on serotonergic 
receptors, with experimental confirmation in a knockout mouse. The author stated that the 
chemical similarity approach is systematic and comprehensive, and may suggest side effects 
and new indications for many drugs. 
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Figure 2.6. The algorithm for Similarity Ensemble Approach (SEA) (A) and its web-
based platform (B).   
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2.5.2 Prediction of Activity Spectra for Substances’ (PASS) 
The concept of Biological Activity Spectrum served as the basis for the „Prediction of 
Activity Spectra for Substances‟ (PASS) software58. Different from other works, which 
focused on predicting a chemical compound‟s interaction with a specific biological entity, Dr. 
Poroikov‟s lab predicts each compound regarding a wide pharmaceutical and toxicological 
profile of activities, which is considered to be a „biological activity spectrum of a substance‟. 
In PASS software version 2006, the prediction is based on a SAR analysis of the 
training set containing more than 60,000 compounds. It uses „Multilevel Neighborhoods of 
Atoms‟ (MNA) as the chemical structure descriptors and the algorithm of the „Activity 
Spectra Estimation‟59as the training procedure. The result of a new compound is presented by 
the activity spectrum, which is the ranked list of the probabilities „to be active‟ Pa, „to be 
inactive‟ Pi, and the type of activity. A compound is considered active if the value (Pa - Pi) 
exceeds the cutoff value, e.g., by default (Pa – Pi) < 0.059. Also, Poroikov‟s group states that 
if Pa > 0.7, the compound is very likely to reveal this activity in experiments, but in this case 
the chance of being the analogue of the known pharmaceutical agents for this compound is 
also high; If 0.5 < Pa < 0.7 the compound is likely to reveal this activity in experiments, but 
this probability is less, and the compound is not so similar to the known pharmaceutical 
agents; If Pa < 0.5 the compound is unlikely to reveal this activity in experiments, but if the 
presence of this activity is confirmed in the experiment the compound might be a New 
Chemical Entity. 
  
34 
 
 
Figure 2.7. The software platform for the Prediction of Activity Spectra for Substances 
(PASS).  
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2.6 Comparison of the generic multi-target technique versus single target model 
building 
We comprehensively compared and validated our kNN-QSAR technique with other 
popular multi-target prediction approaches, which include Similarity Ensemble Approach 
(SEA) and Prediction of Activity Spectra for Substances (PASS). Biological targets involved 
in the comparison included 7 GPCR receptors: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2B, 5-HT6, 
5-HT7, and dopamine receptor D5. 
Datasets used for model building and external prediction were extracted from PDSP, 
WOMBAT and ChEMBL. These are leading small molecule chemogenomics databases, 
which contain 2D/3D structures, calculated properties (e.g. logP, Molecular Weight, eTc.) 
and abstracted bioactivities (e.g. binding constants, pharmacology and ADMET data). 
Information were primarily collected from reliable publications (e.g. Journal of Medicinal 
Chemistry) so the labeling was considered accurate. 
The prediction comparison was conducted for both the internal compounds‟ retrieval 
rate as well as the external compounds‟ prediction accuracy for seven cases. Since 
compounds with non-binder labeling were available only in the PDSP database, those non-
binders have to be “shared” with binders from both PDSP and WOMBAT to generate 
classification kNN-QSAR models. For the case of 5-HT1A dataset, classification QSAR 
models were generated separately for the two combinations of datasets: 105 binders and 61 
non-binders from PDSP, and 69 binders from WOMBAT and the same 61 non-binders from 
PDSP. Since SEA used WOMBAT data as their modeling set, the predictive power 
comparison between classification QSAR models generated for binders from WOMBAT 
(with non-binders from PDSP) and SEA approach was considered strictly fair. We compared 
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the internal recovery rate of modeling set compounds performed by kNN-QSAR versus SEA 
using the same training set compounds (both from WOMBAT). To validate their external 
prediction accuracy, we applied the individual kNN-QSAR and SEA models to predict 
unique ligands deposited in ChEMBL. Note that only ligands covered by neither WOMBAT 
nor PDSP were used. The data deposition of binders (including agonists and antagonists) for 
those 7 biological targets in PDSP, WOMBAT and ChEMBL were shown in Figure 2.8.  
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Figure 2.8. Data disposition of 7 different GPCR targets in PDSP, WOMBAT and 
ChEMBL. 
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The internal recovery rate and the external prediction accuracy are shown in Figure 
2.9-2.12. The internal recovery rate of SEA was around or less than 70%, except for the case 
of dopamine receptor D5, which contained only 14 compounds; however, kNN-QSAR 
always achieved 100% for its internal recovery rate. Though only seven cases were tested 
here, we considered these results to be representative for the other cases, as well. The reason 
for the much lower recovery rate SEA had compared to kNN-QSAR may due to the fact that 
only a simple similarity comparison was involved when making a prediction. The prediction 
results would be significantly biased, especially when a set of known ligands for a receptor 
are unevenly distributed in the chemical space. In Figure 2.9 (A), for example, if the 44 
wrongly predicted 5-HT1A binders were diversely distributed in the chemical space, but far 
from the other 25 binders, if only the similarity comparison is considered in the prediction 
process, then those 44 compounds would much more likely to be falsely predicted. Since 
model building is involved in kNN-QSAR method, with rigorous model validation 
procedures, such false predictions would not commonly occur in QSAR. 
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Figure 2.9. Comparison of SEA and kNN-QSAR on internal prediction. kNN-QSAR 
models were built for those 7 GPCR targets individually, and the numbers of binders in each 
modeling sets were shown on top of each bar. The numbers of binders which were correctly 
recovered by either SEA (A) or kNN-QSAR (B) were shown in dark blue. 
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For the predictions of external compounds, the results further highlight the 
advantages of using QSAR over SEA and PASS. SEA, being the worst method, can only 
predict less than half of the external validation set compounds, while QSAR achieves around 
90% for most of the seven cases. The prediction accuracy for PASS is also much higher than 
SEA, though not as good as QSAR. This is because a simple linear regression method is used 
in PASS for its internal model building process. It was noticed that QSAR models generated 
for binders and non-binders from consistent data source (PDSP) have higher external 
predictive power than models generated for binders and non-binders from mixed sources 
(binders from WOMBAT and non-binders from PDSP) (Figure 2.11). The reason for that is 
currently unknown, but we hypothesized it to be related to models‟ applicability domains 
(AD). This hypothesis was further confirmed by results shown in Figure 2.11 (A) and 
Figure 2.12 (B). Both showed the external predictive power for models generated for binders 
from WOMBAT and non-binders from PDSP; however, the external prediction accuracy 
dramatically increased along with the application of AD. Compounds in the ligand sets from 
WOMBAT may be very similar with each other, thus the models built for them have only 
limited AD. 
Because the modeling set compounds for PASS cannot be traced, not necessarily the 
compounds in WOMBAT database, so the model comparison between PASS vs. SEA and 
QSAR were not strict enough. But overall, the performances of PASS models are much 
better than SEA, though not as good as QSAR (Figure 2.13). 
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Figure 2.10. Comparison of SEA and QSAR on external prediction. kNN-QSAR Models 
were generated for binders and non-binders from PDSP. Unique compounds from ChEMBL 
were used as external tests to compare the external predictive power of SEA and QSAR. The 
numbers of compounds in each external test sets are shown on top of each bar and the 
numbers of compounds correctly predicted by either SEA (A) or QSAR (B) are shown in 
dark blue. 
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Figure 2.11. Comparison of kNN-QSAR external prediction for different data sources. 
kNN-QSAR models are generated separately for binders from WOMBAT with non-binders 
from PDSP (A), and binders/non-binders from PDSP (B). Unique compounds from 
ChEMBL were used as external tests to compare the external predictive power QSAR 
generated from different data sources. The numbers of compounds in each external test sets 
are shown on top of each bar, and the numbers correctly predicted by these two types of 
models are shown in dark blue. 
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Figure 2.12. Comparison of PASS and kNN-QSAR on external prediction. kNN-QSAR 
models were generated on binders from WOMBAT and non-binders from PDSP with 
applicability domains applied. Unique compounds from ChEMBL were used for external 
tests to compare the external predictive power of PASS and kNN-QSAR. The numbers of 
compounds in each external test sets are shown on top of each bar in (A), and the numbers of 
compounds within models‟ AD were shown on top of each bar in (B). The numbers of 
compounds correctly predicted by either PASS (A) or kNN-QSAR (B) are shown in dark 
blue.
  
CHAPTER 3 
VALIDATION OF THE CONGRUENCE OF DATA IN DISPARATE SOURCES AND 
IDENTIFICATION OF LOW QUALITY DATA 
 
3.1 Introduction 
The rapidly growing number of chemical annotations deposited in various databases 
represents the arrival of cheminformatics era. However, a significant gap exists between the 
huge amount of data and our capability of data processing and analysis. Herein, I will apply 
cheminformatics approaches to validate the congruence of data deposition in several 
databases and to identify low quality (by means of low signal-to-noise ratio) data sources. 
The success of my study will not only shed light on the consistency and quality of major 
annotated cheminformatics databases, but also provide solid base for the high quality QSAR 
modeling.  
In my work, QSAR models for the same biological targets are generated separately 
for data obtained from different sources, and are applied for inter-database cross-validation. 
Data that models suggest to be dubious are experimentally validated at UNC. These results 
contribute to the development of cheminformatics approaches and influence the process of 
drug discovery by stressing the importance of determining trustworthy data sources and 
highlighting the significance of predictive QSAR modeling. 
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3.2 The Major Annotated Chemogenomics Databases 
3.2.1 PubChem database and the NIH Molecular Libraries Roadmap Initiative 
Early stages in modern drug discovery often involve screening small molecules for 
their effects on a selected protein target or a model of a biological pathway.  Innovative 
technologies developed in recent years enable rapid synthesis and high throughput screening 
of large libraries of compounds in industry. As a result, there is a huge increase in the 
number of compounds available on a routine basis to quickly screen for novel drug 
candidates against new targets/pathways.  In contrast, such technologies have rarely become 
available to the academic research community, thus limiting the academia to conduct large 
scale chemical genomics research. Launched in 2004, the NIH Molecular Libraries Roadmap 
Initiative
60
 aims to change this situation by integrating multiple chemical libraries and 
screening centers. A salient feature of the NIH Initiative is that the Centers are interested in 
any chemicals that may affect a biological pathway or function, regardless of their potential 
to become drugs.  This feature has been elegantly demonstrated by Schreiber, et al. as the 
unique aspect of chemical genetics or chemical genomics research
61
.  From a biological 
perspective, the NIH Initiative would like to address a broader diversity space as well, to be 
able to interrogate any biological pathways or networks with small molecule effectors
62
.  
PubChem
1
, as an essential component of NIH's Molecular Libraries Roadmap 
Initiative, is the largest chemical database in public domains.  As of recently, it includes 
information on more than 31 million chemical structures and bioactivity results from 1644 
high-throughput screening programs. For each entry, it has the links to bioassay descriptions, 
literatures, references, and assay data. The BioAssay database in PubChem provides 
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searchable descriptions of over 1,000 bioassays, including descriptions of the conditions and 
readouts specific to a screening protocol.  
However, many cheminformatics experts still are skeptical about PubChem data 
quality
63
. Many suggest that the major problem comes from the misguided perception that 
cheminformatics software can be directly used to address the needs of the MPL. Simply 
providing a place to deposit data is not sufficient to ensure its optimal use. The data as 
deposited in PubChem are not curated by screening centers. Identification of the PubChem 
data with rather low signal-to-noise ratio requires very thorough and laborious 
cheminformatics approaches. 
3.2.2 NIMH Psychoactive Drug Screening Program (PDSP) 
NIMH Psychoactive Drug Screening Program (PDSP)
64
 Ki Database (or Ki DB) is a 
public database of published binding affinities (specifically, Ki) of drugs and chemical 
compounds for receptors, neurotransmitter transporters, ion channels, and enzymes. This 
resource is maintained mainly by Dr. Brian Roth‟s lab in the University of North Carolina at 
Chapel Hill, and is funded by the NIMH Psychoactive Drug Screening Program (NIMH-
PDSP) as well as by a gift from the Heffter Research Institute. It can be accessed at 
http://pdsp.med.unc.edu/. The Ki DB is the world‟s largest openly available database of 
ligand receptor affinity data and currently houses >47, 000 Ki values on >500 molecular 
targets. Ki-DB represents a curated, fully-searchable database of both published data and data 
internally derived from the NIMH-PDSP. 
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3.2.3 The World of Molecular Bioactivity (WOMBAT) 
The company supporting the publishers of World of Molecular Bioactivity 
(WOMBAT) is founded by Dr. Tudor I. Oprea M.D., Ph.D. in 2002. WOMBAT serves as a 
leading small molecule chemogenomics database, providing high quality information of 
small molecule bioactivity annotations
3
. The database is a collection of chemical annotations 
published in top medicinal chemistry journals such as Bioorganic & Medicinal Chemistry, 
Journal of Medicinal Chemistry, etc. Therefore, it is stated that although the compounds are 
tested in different laboratories, they should have robust and confident binding results. 
3.2.4 Chemical European Molecular Biology Library (ChEMBL) 
ChEMBL is a database of bioactive drug-like small molecules, it contains 2D 
structures, calculated properties (e.g. logP, Molecular Weight, Lipinski Parameters, eTc.) and 
extracted bioactivities (e.g. binding constants, pharmacological and ADMET data). It 
attempts to normalize the bioactivities into a uniform set of end points and units. Also, when 
it is possible, the bioactivities are linked to published assays which are given varying 
confidence levels. The data is extracted and curated from primary scientific literature, and 
cover a significant fraction of the modern drug discovery space. As ongoing effort, additional 
data on clinical trial progress of compounds are being integrated into ChEMBL. 
3.3 Different Data Sources of 5-Hydroxy Tryptamine receptor subtype 1A (5-HT1A) 
Ligands 
3.3.1 5-HT1A Agonists and Antagonists from PubChem 
The Scripps Research Institute Molecular Screening Center deposited HTS data for 5-
HT1A agonists and antagonists into PubChem (PubChem AID: 613, 718, and 755). AID718 
48 
 
and AID613 are confirmatory dose response assays for 5-HT1A agonists, while AID755 is a 
confirmatory dose response assay for 5-HT1A antagonists. Compounds identified from a 
previously described set of experiments entitled "Primary HTS assay for 5-
Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists" and "Primary Cell 
Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor 
Subtype 1E (5HT1E)" were selected for testing in these assays. A cell line containing the 
human 5-HT1A receptor, the promiscuous G-alpha-15 protein (Ga15), and the beta-
lactamase (BLA) reporter gene under control of the nuclear factor of activated T-cells 
(NFAT) promoter was used to measure 5-HT1A agonism. The amount of BLA activity is 
proportional to the concentration of agonist, which was measured with a fluorescent BLA 
substrate. All experimental details are available online  
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=pcassay&term=613). 
In cases where the highest concentration tested (~50 mM) did not result in more than 
50% inhibition or where no curve fit could be achieved, the EC50 was determined manually 
by the observed inhibition at the individual concentrations. Compounds with EC50 values 
greater than 10 mM were considered inactives, and compounds with EC50 equal to or less 
than 10 mM were considered actives. A conservative estimate of the activity score for each 
compound was calculated for which no exact EC50 value was given while maintaining a 
reasonable rank order of all compounds tested. 
The experimental assays‟ protocols are listed below, which were extracted from 
PubChem website.  
“AID718 details the results of a confirmatory screening bioassay for agonists of 5-
Hydroxytryptamine (Serotonin) Receptor Subtype 1A (5HT1A) conducted in the Scripps 
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Research Institute Molecular Screening Center. It is a relatively small dataset with 51 
compounds and with a ratio of 1 active to 6 inactive compounds (15.9% minority class). The 
compounds were selected on the basis of primary HTS assay for agonists of the 5-
Hydroxytryptamine Receptor Subtype 1E (5HT1E) of approximately 64,900 small molecules 
(PubChem AID = 574). 
AID613 is a confirmatory screening assay from the Scripps Research Institute 
Molecular Screening Center for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a 
(5HT1A) agonists, which consists of 346 compounds with a ratio of one active compound to 
19 inactive compounds (5.2% minority). The compounds have been selected for their 
activation results in the Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor 
Subtype 1a (5HT1A) agonists of approximately 64,900 compounds (PubChem AID = 567). 
AID755 is the result of a confirmatory screen for Antagonists of the 5-
Hydroxytryptamine Receptor Subtype 1A (5HT1A) from the Scripps Research Institute 
Molecular Screening Center. It contains activity information of 44 compounds with a ratio of 
one active compound to 0.76 inactive compounds (131.6% minority). The screen is a 
reporter-gene assay and the tested 44 compounds were selected from the primary HTS assay 
for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1A) agonists and antagonists 
of approximately 64,900 compounds (PubChem AID = 567 and 574).” 
We assume that all agonists and antagonists are 5-HT1A binders. There are seven 
agonists identified through AID718, and 17 from AID613, however, 3 of them were identical 
structures. So 21 agonists and 25 antagonists were confirmed by PubChem dose response 
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assay in total (there is no shared chemicals identified to be agonists and antagonists at the 
same time). 
3.3.2 5-HT1A Binders and Non-binders from PDSP 
The NIMH Psychoactive Drug Screening Program (PDSP) database, which is 
maintained by Dr. Bryan Roth‟s lab, collects primary and secondary binding assays for many 
GPCR receptors, including 5-HT1A receptor. In their assays, each compound was added 
quadruplicate to 96-well format plate and radioligand was used to measure the fraction of the 
target compound that binds with the crude membrane fractions of cells expressing 
recombinant 5-HT1A receptors. Radioligands were purchased by PDSP from Perkin-Elmer 
or GE Healthcare. Competition binding assays were performed using transiently or stably 
expressing cell membrane preparations as previously described
65, 66
, and are available online 
(http://pdsp.med.unc.edu). The radioligand used for 5-HT1A binding assays was [
3
H]-8-OH-
DPAT. All experimental details are available online (http://pdsp.med.unc.edu/UNC-
CH%20Protocol%20Book.pdf). 
All chemical structures and binding affinity information were deposited in PDSP Ki 
database, in which we retrieved the 5-HT1A binders and non-binders using their online 
search engine. In this study, we used 1mM as the cutoff value to define binders vs. non-
binders, and we only retrieve ligands tested against cloned human cell lines using the hot 
ligand of [
3
H]-8-OH-DPAT. By submitting such queries, 105 unique compounds were 
extracted to be 5-HT1A binders, with binding affinity less than 1mM. There are 61 non-
binders which were shown to have no binding to the 5-HT1A receptor at 1mM concentration, 
but share relatively high structural similarity with those 105 binders. 
51 
 
3.3.3 5-HT1A Binders from WOMBAT 
World of Molecular Bioactivity, WOMBAT, served as a leading small molecule 
chemogenomics database and the standard of quality in small molecule bioactivity 
annotations
67
. Compounds were tested in different labs but with robust and confident binding 
results. 5-HT1A binders were extracted from WOMBAT when they satisfied all the 
following thresholds: 1) Compounds were tested on cloned human species cell lines; 2) [
3
H]-
8-OH-DPAT were used as the hot ligand in the experiments; 3) The compounds‟ binding 
affinities were lower than 1mM concentration. In such case, only 60 unique compounds were 
chosen. 
 
3.3 Methods 
3.3.1 Datasets Curation and Descriptors Generation 
The SMILES 
68
 strings of each compound in 5-HT1A dataset were converted to 2D 
chemical structures using the Molecular Operating Environment (MOE) software package. 
The Dragon 
7
 software (version 5.5) was used to calculate a wide range of topological indices 
of molecular structure. These indices include (but are not limited to) the following 
descriptors: simple and valence path, cluster, path/cluster and chain molecular connectivity 
indices 
69-71
, kappa molecular shape indices 
72, 73
, topological and electrotopological state 
indices 
74-76
, differential connectivity indices,
 
graphs‟ radius and diameter 77, Wiener and 
Platt indices, Shannon and Bonchev-Trinajstić information indices, counts of different 
vertices, counts of paths and edges between different kinds of vertices. 
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Overall, Dragon produced over 2,000 different descriptors. Most of these descriptors 
characterize chemical structure, but several depend upon the arbitrary numbering of atoms in 
a molecule and are introduced solely for bookkeeping purposes. In our study, only 880 
chemically relevant descriptors were initially calculated and 672 descriptors were eventually 
used for 5-HT1A binding datasets after deleting descriptors with zero value or zero variance. 
Dragon descriptors were range scaled prior to distance calculations since the absolute scales 
for Dragon descriptors can differ by orders of magnitude
78
. Accordingly, our use of range-
scaling avoided giving descriptors with significantly higher ranges a disproportional weight 
upon distance calculations in multidimensional Dragon descriptor space. 
3.3.2 Training, Test, and External Validation Set Selection 
We have followed the rigorous QSAR workflow for model building, validation and 
database mining (Figure 2.2) established in our laboratory (see 
79
 for recent overview). For 
classification QSAR modeling, it would be ideal to have the balanced ratio between different 
compound classes in the modeling dataset. However, the 5-HT1A binding dataset from PDSP 
includes 105 inhibitors and 61 non-binders, i.e., thus it is imbalanced with the inhibitors to 
non-binders ratio of 5:3; while 69 compounds from WOMBAT are all binders, and he 
PubChem dataset contains 46 binders and 389 non-binders. In the absence of special 
statistical treatment, such imbalanced datasets will distort the QSAR model prediction; 
therefore, we conducted different strategies for model building on those multiple datasets. 
For PDSP [105/61] dataset, we do not want to lose any 5-HT1A binding data information, so 
different weights for 5-HT1A binders and non-binders were employed during the modeling 
process. As for 69 WOMBAT binders, we combine them with PDSP non-binders (61 in total) 
[69/61] to build classification QSAR models. Because PubChem dataset has the largest 
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inhibitors to non-binders ratio, being roughly 1:8, such a ratio would largely skew the 
prediction accuracy of the classification models in the absence of special statistical treatment. 
Thus, the distance matrix was calculated in the multidimensional descriptor space for all 435 
compounds and a similarity search was carried out using 46 inhibitors as queries against the 
remaining 389 non-binders. 58 compounds were selected from the original 389 non-binders 
as most similar to the 46 inhibitors using Zcutoff value of 0 (we note that this treatment makes 
the task of building the discriminatory binary QSAR models even more challenging). 
Consequently, these 58 non-binders combined with 46 PubChem inhibitors formed a new 
balanced dataset for QSAR model building.  Furthermore, the five-fold external set cross 
validation protocol was conducted when building models for those three datasets. For each of 
the five fold, one-fifth of the compounds from the total 166 were randomly chosen as one 
external validation set, so that each compound will be in the external validation set once and 
only once.  The remaining four-fifth of the compounds were considered a modeling dataset 
that was divided into multiple diverse and representative training and test sets using the 
Sphere Exclusion approach developed in our laboratory earlier 
80, 81
. 
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3.3.3 QSAR Models Generated from Disparate Data Sources 
 We followed the conventional kNN classification model building workflow 
developed in our lab to generate high qualify QSAR models, herein, the value of 0.8 was 
used for both CCRtrain and CCRtest. RF was conducted in the R software using the package of 
RF (randomForest). SVM was conducted in the WinSVM software available in our lab, 
which implemented the conventional LIBSVM methodology. For all three methods, the same 
modeling set compounds were used to generated models, and the same external validation set 
compounds were applied, as well. 
3.3.2 QSAR Model-Based Cross Validation between Disparate Data Sources 
After building Classification QSAR models on binders/non-binders from PDSP, 
binders in WOMBAT with non-binders in PDSP, and binders/non-binders from PubChem, 
and these models were used to cross validate 5-HT1A compounds between different sources, 
i.e. the combinatorial QSAR models generated by kNN, RF and SVM on binders/non-binders 
from PDSP were used to validate 69 binders from WOMBAT and 46 agonists/antagonists 
from PubChem (PubChem Assay ID (AID): 613, 718 and 755). The application domain was 
also applied using Zcutoff = 0.5. Some of the validation results for PubChem confirmatory 
compounds were set as non-binders by our models and were further experimentally tested in 
Dr. Bryan Roth‟s lab at UNC, Chapel Hill. 
3.4 Results and Discussions 
3.4.1 QSAR Classification Models 
The kNN QSAR method with variable selection afforded models with optimal 
accuracy characterized as CCR for both training and test sets. For kNN classification models 
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generated on 105 5-HT1A binders and 61 non-binders from PDSP, there were 838 models 
with both CCRtrain and CCRtest equal or higher than 0.80. Most models with CCRtest  ≥ 0.80 
also had corresponding CCRtrain ≥ 0.80, but the opposite was not always true. The models 
with high values of both CCRtrain and CCRtest (≥ 0.80) were considered acceptable and were 
selected for consensus prediction. The CCRtrain and CCRtest for the best kNN model are 0.91 
and 0.99 respectively, implying that the model could correctly identify 51 binders out of 55 
and 34 out of 38 non-binders (SE = 0.93, SP = 0.89, EN(1) = 1.80, and EN(2) = 1.85) in the 
training set and almost all binders and non-binders in the test set. This remarkably high 
internal accuracy and the large number of acceptable models imply that the kNN 
classification method was generally successful in correctly distinguishing binders vs. non-
binders using Dragon chemical descriptors. 
For kNN classification models generated on 69 5-HT1A binders from WOMBAT and 
61 non-binders from PDSP, both the internal and external model statistics are even higher. In 
total, there were over 30,000 models with both CCRtrain and CCRtest equal or higher than 0.80, 
in which 6,234 models were over 0.90. Due to the extremely large number of qualified 
models, we chose to only use models with CCRtrain and CCRtest equal or higher than 0.90 to 
perform further five-fold cross validation. 
QSAR models generated for agonists/antagonists with non-binders from PubChem 
database had much worse statistics than the previous two. There were in total 7,852 models 
having both CCRtrain and CCRtest equal or higher than 0.50, and only 123 models higher than 
0.80. These statistics were very close to those obtained with Y-randomization test, which 
suggests rather low model quality and confidence. 
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3.4.2 Validations of QSAR Classification Models 
In addition to the internal validation of kNN models using test sets, Y-randomization 
and external validation are the critical steps of the entire QSAR workflow (Figure 1). Only 
models that have been validated by these two steps can be utilized for external prediction and 
validation 
48
. 
3.4.2.1 Y-randomization Test 
 In the Y-randomization test, the binary annotations of 5-HT1A as binders or non-
binders were randomly shuffled and kNN, RF and SVM classification models were built with 
the same parameter setting. The test was performed three times for each training/test set split 
for datasets from PDSP, WOMBAT and PubChem, respectively. All runs of Y-
randomization tests showed that there were relatively small number of models having both 
CCRtrain and CCRtest higher than 0.70. However, there were only few (less than five) models 
with both CCR values higher than 0.80 (Figure 2). Notice that the CCR values generated in 
Y-randomization tests using either PDSP or WOMBAT datasets were much worse than the 
ones using real binding affinities. In contrast, the CCR values generated in PubChem model 
building based on either real or randomized activities were very close. It implied that the 
QSAR models obtained from PDSP and WOMBAT datasets with both CCRs greater than 
0.80 were robust models, while models built for PubChem data were not reliable. As we will 
show, these results can also mean that data from PDSP and WOMBAT are more reliable than 
PubChem data depositions. 
3.4.2.2 External Set Validation 
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The five-fold cross-validation (see above) was employed to evaluate the predictive 
power of QSAR models. Consensus prediction by all kNN models with CCRtrain and CCRtest 
greater than 0.8 was carried out, and the final prediction score was the average of predicted 
class labels over all models for which a compound was within the AD, which was defined by 
Zcutoff value of 0.5. Also, a compound was considered out of the AD if it was predicted by 
less than 50% of the models. For validation of models generated by Random Forest and 
Support Vector Machine, exactly the same five-fold external cross-validation sets were used. 
The average prediction results for all five-fold predictions of dataset from PDSP, WOMBAT 
and PubChem were summarized in Table 3.1 and the detailed prediction statistics for each 
five-fold were available in Table S1 of supporting materials. Under Zcutoff = 0.5, most CCRevs 
achieved a rather high prediction accuracy for datasets from PDSP and WOMBAT. Those 5-
HT1A binders falsely predicted (average class number > 1.5) were within an applicability 
domain of only a small portion of qualified kNN models, which were usually considered as 
unreliable predictions. In summary, QSAR models generated for 5-HT1A dataset from PDSP 
and WOMBAT with both CCRtrain and CCRtest equal to or greater than 0.80 gave high 
consensus prediction accuracy in the corresponding five-fold external validation.  
On the other hand, the five-fold cross validation statistics for QSAR models 
generated on PubChem 5-HT1A data were much worse than PDSP and WOMBAT data, 
shown in Table 3.1. The average five-fold CCRevs was only 0.59, statistically not different 
than the CCRevs value of 0.48, which was obtained in the Y-randomization test. These results 
implied that the QSAR models generated on PubChem data were not robust and not 
predictive. 
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Table 3.1. External validation statistics for disparate 5-HT1A datasets by different QSAR methods 
Datasets Machine Learning 
Methods 
Prediction 
CCR 
Confusion Matrix  Statistics 
N(1)a N(2)a TP TN FP FN  SE SP EN(1) EN(2) 
 k-Nearest Neighbor 0.76 (0.111) 104* 61 94 38 23 10  0.89 (0.084) 0.61 (0.177) 1.41 (0.212) 1.70 (0.229) 
PDSP Random Forest 0.80 (0.095) 105 61 93 41 20 12  0.88 (0.099) 0.68 (0.098) 1.46 (0.122) 1.72 (0.206) 
 Support Vector Machine 0.80 (0.106) 105 61 98 41 20 7  0.93(0.043) 0.68(0.176) 1.50(0.229) 1.80(0.142) 
 k-Nearest Neighbor 0.93(0.034) 69 61 67 54 7 2  0.97(0.034) 0.90(0.046) 1.79(0.086) 1.94(0.080) 
WOMBAT Random Forest 0.91(0.050) 69 61 65 54 7 4  0.94(0.064) 0.89(0.042) 1.78(0.082) 1.88 (0.129) 
 Support Vector Machine 0.87(0.089) 69 61 59 54 7 10  0.85(0.095) 0.89(0.086) 1.74(0.132) 1.72(0.184) 
 k-Nearest Neighbor 0.59(0.110) 45* 58 24 38 20 21  0.54 (0.188) 0.66 (0.102) 1.21 (0.258) 1.20 (0.226) 
PubChem Random Forest 0.59(0.100) 46 58 25 38 20 21  0.51(0.152) 0.67(0.210) 1.30(0.415) 1.16(0.191) 
 Support Vector Machine NA 46 58 NA NA NA NA  NA NA NA NA 
 
a
 N(1) = number of inhibitors, N(2) = number of non-binders, TP = true positive (inhibitors predicted as inhibitors), FP = false positives (non-binders predicted as 
inhibitors), FN = false negatives (inhibitors predicted as non-binders), TN = true negative (non-binders predicted as non-binders), SE = sensitivity = TP/N(1), SP 
= specificity = TN/N(2), EN - the normalized enrichment, EN(1) = (2TP * N(2))/(TP * N(2) + FP * N(1)), EN(2) = (2TN * N(1))/(TN * N(1) + FN * N(2)), and 
CCR = correct classification rate. 
* There is one compound in external set 1 that not within the applicability domain using Zcutoff = 0.5. 
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3.4.3 Inter-dataset Cross Validation 
3.4.3.1 Applicability Domains of Models Generated for Various Datasets 
To cross validate the 5HT1A models generated from three datasets, the applicability 
domains of the three datasets‟ were evaluated first. We applied the global similarity search 
approach, which involved all 672 Dragon descriptors, to search for structurally similar 5-
HT1A binders in each of datasets using binders from one of the other datasets as probes. By 
applying different Zcutoff values, the percentage of compounds that were identified within AD 
in each data source was shown in Figure 2. Regardless of dataset sources, the number of 
compounds within AD increased by raising the Zcutoff values. When using 5-HT1A binders 
from WOMBAT for global similarity search, the least number of compounds were included 
within AD in both PDSP and PubChem dataset, indicating that the compounds from 
WOMBAT had very limited structural diversity, and thus the corresponding models had the 
smallest AD compared to other models. The chemicals from PDSP had greater structural 
diversity and the AD for the corresponding models was considerably wider. The compounds 
from PubChem had the most diverse structures, and nearly all compounds from either PDSP 
or WOMBAT were chosen using Zcutoff of 0.5. 
In order to perform the inter-dataset cross validation, both the model prediction 
accuracy and applicability domain should be taken into consideration. Models for PDSP and 
WOMBAT were both predictive, but models for PDSP had a much boarder AD than those 
for WOMBAT. Therefore, PDSP models were the most suitable to use for the validation of 
5-HT1A binders from WOMBAT and PubChem. 
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Figure 3.1. The similarity search results of 5-HT1A binders for each dataset using 
binders from the other dataset as probes.  
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3.4.3.2 WOMBAT Data Validation 
We used models built for PDSP dataset (containing 105 5-HT1A binders and 61 non-
binders) to verify the 69 5-HT1A binders from WOMBAT. The complete modeling set (i.e., 
including training and test sets) was used for the prediction as opposed to using only the 
corresponding training set. Among the 69 binders extracted from WOMBAT, all were within 
the applicability domain, and 65 were accurately annotated by kNN consensus prediction 
(CCR = 0.95, Table 2). The majority of ligands had been predicted correctly by kNN models, 
and for the only four falsely predicted 5-HT1A binders by kNN, they were within the 
applicability domain of only 70 models (i.e., approximately 30% of all models). As the 
model coverage was as low as 30% and the prediction scores were less than 1.70, these 
compounds‟ predictions were considered as low confidence. Similar consensus prediction 
results were achieved by both RF and SVM (Table 2), which confirmed that our models 
were both accurate and robust. 
 
  
62 
 
Table 3.2. The cross-validation of 69 WOMBAT 5-HT1A inhibitors by consensus prediction 
of acceptable QSAR models that were generated for PDSP dataset. 
 
QSAR Methods 
 
Prediction CCR 
Confusion Matrix  Statistics 
N(1) N(2) TP FN  SE 
k-Nearest Neighbor 0.94 69 0 65 4  0.94 
Random forest 0.94 69 0 65 4  0.94 
Support Vector Machines 0.96 69 0 66 3  0.96 
 
 
 
 
Table 3.3. The cross validation of 46 PubChem confirmatory 5-HT1A agonists/antagonists 
by consensus prediction of acceptable QSAR models that were generated for PDSP dataset. 
 
QSAR Methods 
 
Prediction CCR 
Confusion Matrix  Statistics 
N(1) N(2) TP FN  SE 
k-Nearest Neighbor 0.48 46 0 22 24  0.48 
Random forest 0.35 46 0 16 30  0.35 
Support Vector Machines 0.56 46 0 26 20  0.56 
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3.4.3.3 PubChem Data Validation 
All qualified models built for PDSP dataset were used to cross validate the 5-HT1A 
dataset from PubChem. In total of 21 5-HT1A agonists and 25 antagonists were found in 
PubChem dose response (confirmatory) assays (PubChem Assay ID: 613, 718 and 755). The 
consensus predictions were made by kNN, RF and SVM; however, 25 out of 46 were 
predicted non-binders by kNN, with 14 of those 25 having consensus prediction value higher 
than 1.70. These results strongly suggest that many of the agonists/antagonists reported in 
PubChem dose response (confirmatory) assays may be false positives. By applying random 
forest and support vector machines, the number of non-binders predicted was 30 and 20 
respectively, out of the 46 total agonists/antagonists. 14 chemicals were predicted to be non-
binders by all these three methods. 10 of them were commercially available, and were sent 
for further experimental validation at UNC.  
3.4.4 Experimental Validation 
Of the 14 false positive PubChem chemicals predicted by all three methods, kNN, RF 
and SVM, there are 9 compounds commercially available, and were further tested 
experimentally in Dr. Bryan Roth‟s lab at UNC. All nine compounds (PubChem CID: 
130606, 890649, 659822, 708260, 3242053, 733831, 597363, 2860584, 660939 Table 5) 
failed to achieve the 50% inhibitory activities at the single concentration assay. The most 
potent compound has the percentage of inhibition at 10 µM being 43.0% while the weakest 
being only 10.6%. Although these experimental results confirm our QSAR models‟ 
prediction, the fact of such high false positive rate in PubChem data is still surprising to us 
because all the annotated agonists/antagonists are confirmed hits in dose-response cell-based 
assay conducted by the Scripps Research Institute Molecular Screening Center. In summary, 
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the above results did prove the high predictive power of our binary kNN, RF and SVM 
classification QSAR models built for the 5-HT1A dataset. These studies illustrate that the 
validated QSAR workflow, as employed in this paper, could be used as a general tool for 
identifying potential false positives and false negatives in assay results with low data quality. 
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Table 3.4. The experimental validation of 5-HT1A binding affinity test for PubChem confirmatory agonists/antagonists. 
Structure 
Serial 
No. 
PubChem 
ID 
PubChem 
label 
kNN 
prediction 
score 
RF 
prediction 
score 
SVM 
prediction 
score 
SEA 
prediction 
Exp. 
Percent of 
inhibition
a
 
 
1 130606 Antagonist 1.97 1.76 2.00 Negative 12.10%b 
 
2 890649 Antagonist 1.86 1.76 2.00 Negative 10.60% 
 
3 659822 Antagonist 1.86 1.70 1.75 Negative 30.50% 
 
4 708260 Agonist 1.82 1.70 2.00 Negative 15.60% 
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5 3242053 Antagonist 1.75 1.81 2.00 Negative 43.00% 
 
6 733831 Agonist 1.73 1.78 2.00 Negative 28.10% 
 
7 597363 Antagonist 1.73 1.77 2.00 Negative 20.30% 
 
8 2860584 Antagonist 1.73 1.66 2.00 Negative 20.10% 
 
9 660939 Antagonist 1.71 1.69 1.94 Negative 16.10% 
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a
: All nine commercially available PubChem compounds were sent to experimental validation for their 5-HT1A percent of inhibition test. 
Compounds with the percent of inhibition less than 50% are considered non-binders. 
b
: The full IC50 curves were generated in further experiment and were available in supplementary materials. 
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3.5 Conclusions 
Our studies demonstrate that classification QSAR models can accurately differentiate 
true 5-HT1A binders from non-binders in reliable data sources, such as PDSP and 
WOMBAT. By contrast, we fail to generate qualified models using unreliable datasets, for 
example, data deposited in PubChem. The combinatorial QSAR modeling scheme is 
employed for all three 5-HT1A datasets and the models are rigorously validated using both 
internal (multiple training/test sets, Y-randomization test) as well as external validation (five-
fold cross validation). We have demonstrated that this strategy affords QSAR models with 
high internal and external predictive power. As part of our QSAR modeling workflow, the 
predictors are further utilized for cross-validation of the 5-HT1A datasets from different 
sources. We find that the prediction results of our validated models highly agree with the 
experimental annotation of 69 5-HT1A binders as reported in WOMBAT database. 
Furthermore, the PubChem binders, which were identified by cross-validated QSAR models 
as false positive, were sent for experimental testing. The experimental results highly agreed 
with our models‟ consensus predictions and confirmed that those confirmatory assay hits 
deposited in PubChem are false positives. 
 
  
CHAPTER 4 
DEVELOPMENT OF THE “DIVIDE-AND-CONQUER” QSAR MODELING 
SCHEME FOR RECA INHIBITORS AND VIRTUAL SCREENING FOR 
IDENTIFYING NOVEL CHEMICAL SCAFFOLDS 
 
4.1 Introduction 
Good model building methodologies should take into consideration the different 
characteristics of modeling datasets, thus should vary case by case. Conventional QSAR 
approaches use various machine learning methods to build models and perform predictions, 
in regardless of caring about the high experimental variability of input data for model 
building. In this chapter, QSAR models would be generated to help identify those input data 
with low quality, and thus generate high quality models based on the curated dataset. 
Moreover, novel algorithms of the “divide-and-conquer” approach were developed based on 
existing QSAR classification methods to improve the performance of classifiers for largely 
imbalanced, sparsely structured datasets. These new algorithms outperformed traditional 
QSAR algorithms in mining the imbalanced RecA inhibitors dataset. Model-based virtual 
screening was performed thereafter, by mining 6.6 million molecules compiled from 
ZINC7.0 database, World Drug Index, and TimTec Diversity Set 10K. Proposed 11 
computational hits were further experimentally tested against RecA ATPase activity assays, 
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and five were confirmed to be active against RecA. This new algorithm of QSAR approach 
demonstrated a unique edge in discovering chemical patterns for lead optimization. 
4.1.1 Introduction for RecA Protein Inhibitors 
The discovery of antibiotics, being one of the most important success stories in 
human medicine of the 20th century, has eased suffering and saved millions of lives in 
countless patients. However, antibiotic resistance in pathogenic bacteria is an escalating 
problem over time, making infections difficult if not impossible to treat. In the United States, 
infections encountered in the hospital or a health care facility affect more than 2 million 
patients, contributing to 88,000 deaths annually
82
. Notably, roughly 70% of those infections 
are resistant to at least one drug. Moreover, antibiotic drugs have accounted for $23 billion in 
worldwide sales, making them the second largest therapeutic category in terms of sales. 
Therefore, the trend towards increasing numbers of infection, with the accelerating pace at 
which drug resistance increases, has provided huge research and business opportunities for 
novel antibiotic drug discovery. 
New antibiotics discovered by traditional attempts, which mainly focus on finding 
new ways to combat bacteria, will be slow in coming to market due to the increasing rate that 
drugs develop resistance. Consequently, finding ways to combat antibiotic resistance directly 
is needed and might shed light on the discovery of novel antibiotic classes. Although the 
mechanisms by which antibiotic resistance evolves and spreads are not fully understood, the 
rapid rate at which bacteria develop drug resistance is largely due to mutations arising during 
mutagenic DNA synthesis and gene transfer between organisms.  One protein central to both 
the development and transmission of antibiotic resistance is RecA, which is found in almost 
all bacteria and likely plays similar roles in all species.  RecA is activated when the 
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bacterium is under stress and cannot divide in the usual way, thus acts as the foreman for a 
crew of repairman 
83
. Therefore, it has been suggested that finding ways to inhibit RecA 
protein would open up a number of infectious therapeutic possibilities
84
. For example, using 
a RecA inhibitor in combination with mitomycin C, ciprofloxacin, or another DNA damaging 
antibiotic could provide a therapeutic strategy for treating NIAID class A and B pathogens. 
Furthermore, the discovery of RecA inhibitors might elucidate the molecular mechanisms 
related to the evolution of antibiotic drug resistance. Bacteria initiate the “SOS response”, 
which is initiated and controlled by RecA, when under attack by medicines and on the brink 
of destruction. Without RecA, the bacterial population‟s ability to develop drug resistance 
would be suppressed.  
Current discoveries of RecA inhibitors are encouraging but limited. The efforts of 
high-throughput screening encompass several classes of synthetic RecA inhibitors, including 
ATP-competitive small molecules, designed peptides, and select organometallic complexes
85
. 
However, these hits inhibit RecA protein with rather low potency. Thus there has been great 
need for potent RecA inhibitors of novel chemical scaffolds. The recent progress in model-
based virtual screening has made the discovery of new chemicals more accurate and reliable; 
in addition, more diverse data in very large quantities have become available, allowing more 
opportunities for more focused hypothesis building. The paradigm is then beginning to 
change towards generating more focused structural hypotheses calling for much more limited 
testing of a smaller number of compounds with much higher probabilities of success; thus the 
experiment are being run to conform specific predictions rather than in a hope that some of 
the predicted hits may turn out useful. In this study, a unique modeling scheme that combines 
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unsupervised clustering with combinatorial QSAR methods was introduced for the discovery 
of novel scaffolds of RecA inhibitors. 
4.1.2 RecA Dataset 
4.1.2.1 First Version of RecA Dataset 
The biological data for 3,488 compounds (53 inhibitors and 3,435 non-inhibitors) 
used in this study were generated in Dr. Singleton‟s laboratory. Compounds were tested by 
high-throughput screening against RecA‟s ATPase activity, and those with a percentage of 
inhibition at 17µM higher than 50% were subjected to the subsequent confirmatory binding 
assays
85
. Only limited number of primary hits were confirmed, therefore, additional RecA 
inhibitors were designed by Dr. Singleton according to those confirmed hits and were tested 
again, making the total number of RecA inhibitors to be 53. These confirmed RecA protein 
inhibitors have the inhibition IC50 range from 0.5 to 250. For the purpose of this work, we 
curated the data set to exclude duplicates within each group (inhibitors and non-inhibitors), 
and select the subset of organic compounds. Inorganic and organometallic compounds, as 
well as compound mixtures, were excluded because conventional chemical descriptors used 
in QSAR studies could not be computed in these cases. Also, 54 non-inhibitors were chosen 
based on a high structural similarity with the 53 inhibitors. 
4.1.2.2 Second Version of RecA Dataset 
The RecA dataset comprised of 26,433 compounds (145 inhibitors and 26,288 non-
inhibitors) were generated after the curation of the first version of RecA dataset and the 
combination of additional up-to-date screening results from Boston University, IOC and Dr. 
Singleton‟s laboratory. Similar to the above curation procedure, duplicates were removed and 
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the main subsets of organic compounds were kept. Using global AD, 185 non-inhibitors were 
chosen based on high structural similarity with the 145 inhibitors. 
4.1.3 Libraries for Virtual Screening 
The virtual screening was performed on our in-house collection of ca. 6,600,000 
molecules, including the ZINC database of ca. 6,500,000 compounds
86
, the World Drug 
Index (WDI) database of ca. 59,000 compounds
87
, and the TimTec Diversity library of 
10,000 compounds. None of the compounds present in the modeling set were found in the 
screening libraries. Dragon 2D topological descriptors were calculated for each compound in 
the databases and linearly normalized based on the maximum and minimum values of each 
descriptor type in the modeling dataset of  145 RecA inhibitors and 185 non-inhibitors.  
 
4.2 Methods 
4.2.1 Generation of Descriptors and Dataset Split 
4.2.1.1 Generation of 2D Molecular Descriptors 
All chemical structures were cleaned using the wash function in MOE2007.09 to 
remove all but the largest fragment.  Missing hydrogens were added during this procedure. 
The software of DRAGON2007-5.5 was used to calculate over 2,000 descriptors. Most of 
these descriptors can characterize chemical structures, including constitutional descriptors, 
walk and path counts, and functional group counts. In our study, 2D binary fingerprints and 
2D frequency fingerprints were not included, and 698 chemically relevant descriptors 
remained after the removal of those descriptors with zero values or zero variance prior to 
model generation. The descriptor values were then linearly normalized to fall within a range 
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between zero and one based on the maximum and minimum values of each descriptor (i.e., 
range-scaled).  Normalization was required to prevent unequal descriptor weighting during 
the QSAR model generation process as described below. 
 
4.2.1.2 Selection of External Validation Sets, Training and Test Sets 
In order to obtain external sets containing the same distribution of inhibitors and non-
inhibitors as the original set, and also to increase the predictive statistical value, a five-fold 
Cross Validation (CV) analysis was performed for the whole dataset containing RecA 
inhibitors and non-inhibitors. The dataset was randomly split into five equal-size subsets of 
compounds and five independent sets of calculations were conducted, each of which involves 
only four-fifth of the compounds for model building and selection, and the remaining one-
fifth of the compounds as an external test set.  
The data set was subdivided into multiple training/test set pairs using the sphere 
exclusion method developed in our laboratory
88, 89
. By default, fifty different training/test set 
splits were initially tried using probe sphere radii defined by the minimum and maximum 
elements, Dmin and Dmax, of the distance matrix D between compound-vectors in the 
descriptor space and 42 splits were ultimately accepted. The number of compounds in the test 
set was varied to achieve the largest possible size of the test set, while ensuring that the 
training set models were still able to accurately predict the binding affinity of the test set 
compounds. 
4.2.2 Model-based Data Curation and Activity Cliffs Identification 
4.2.2.1 Similarity Search and QSAR Models Generation 
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For classification QSAR modeling, it would be ideal to have the balanced ratio 
between different compound classes in the modeling dataset. However, with the first version 
of RecA dataset containing 53 inhibitors and 3,435 non-inhibitors, the RecA dataset was 
imbalanced. In the absence of special statistical treatment, such a ratio would skew the 
prediction accuracy of the classification models. Therefore, a similarity search was 
performed against 3,435 RecA non-inhibitors using those 53 inhibitors as probes, and 55 
compounds were chosen. All 698 Dragon descriptors were involved in this process, which 
was conducted by the software written in house. 
We have followed the conventional kNN QSAR workflow for model building, and 
vigorously validated our models using both multiple internal test sets and five-fold external 
cross validation sets 
90
. 
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4.2.2.2 Identification of Compound Pairs with Activity Cliffs 
 The first version of RecA dataset containing 53 inhibitors and 55 non-inhibitors were 
first clustered using hierarchical clustering method using R software. Then, we calculated the 
Tanimoto Coefficient (Tc) values for each pair of compound structures represented by 698 
Dragon descriptors, and ploted the different values in heatmap. RecA compound pairs with 
activity cliffs were then identified. Several pairs with highly similar structures but opposite 
RecA inhibitory profiles were analyzed and further tested experimentally again. 
4.2.3 “Divide-and-Conquer” QSAR Modeling Scheme for Curated RecA Dataset 
The second version of RecA dataset largely increased in size as well as structural 
diversity. Therefore, the dataset were first analyzed by the hierarchical cluster approach in 
the software of R. Three distinct groups of RecA inhibitors were identified according to their 
structural similarity between each other. A similarity search was then performed individually 
against RecA non-inhibitors using inhibitors in each group as probes, and three groups of 
RecA dataset were generated. The QSAR approach involving kNN, RF and SVM were 
conducted separately, followed by the rigously internal and external validation. 
In addition, a Y-randomization test was carried out to establish model robustness. The 
test consists of rebuilding models using shuffled activities of the training set and evaluation 
of such models‟ predictive accuracy in comparison with the original model. It is expected 
that models obtained for the training set with randomized activities should have significantly 
lower values of statistical parameters such as CCRtrain and, especially, CCRtest. Therefore, if 
most QSAR models generated in the Y-randomization test exhibit relatively high values of 
the statistical parameters for both training and test sets, it implies that a reliable QSAR model 
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cannot be obtained for the given dataset. This test was applied to all QSAR approaches in 
this study and was repeated twice for each division. 
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Figure 4.1. The workflow of the “Divide-and-Conquer” QSAR modeling approaches as 
applied to the RecA dataset.  
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4.2.4 QSAR-based Virtual Screening  
As illustrated in the workflow shown above, the rigorously validated combinatorial 
QSAR models were employed for virtual screening. In total of 6.6 million compounds 
rendered the virtual screening process, including World Drug Index, ZINC7.0 database, and 
TimTec Diversity Set 10K. First, a global applicability domain was applied in the complete 
descriptor space in order to filter out compounds that differed in their structures from the 
modeling set compounds. All compounds filtered by the global AD were further put into the 
combinatorial QSAR approach for their RecA inhibitory predictions. Because robust QSAR 
classification models were successfully built for only compounds in group 1 and group 2, the 
global similarity search were applied separately using compounds in these two groups. We 
should point out that the chemical spaces represented by these two groups were different, so 
few compounds were chosen by these two similarity searches at the same time. During the 
consensus prediction, the results were accepted only when the compound was found within 
the applicability domains of more than 50% of all models used in consensus prediction and 
the standard deviation of estimated means across all models was small. Furthermore, we 
restricted ourselves to the most conservative applicability domain for each model using Zcutoff 
= 0.5. 
4.2.5 Experimental Validation of Virtual Screening Hits 
For all virtual hits chosen by consensus predictions of kNN, RF and SVM, 11 
chemicals were further selected including one compound from World Drug Index, 1 from 
ZINC7.0 database, and nine from TimTec Diversity Set 10K. These structurally diverse and 
commercially available hits were purchased from different suppliers and experimentally 
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tested in Dr. Scott Singleton‟s laboratory for measuring their RecA ATPase inhibition 
activity. 
4.3 Results and Discussions 
4.3.1 QSAR Classification Models On First Version Dataset 
The first version of RecA dataset contains 53 RecA inhibitors and over 3,435 non-
inhibitors. Descriptors were first generated for all compounds using DRAGON software 
2007. The group of non-inhibitors, representing diverse structural classes, have only limited 
numbers of compounds sharing the same structural classes as active ones, while most others 
have structures highly dissimilar from those included in the group of RecA inhibitors. 
Therefore, in order to prevent the model building and validation from being biased toward 
correct prediction of the larger group, the RecA non-inhibitors, a similarity search was 
performed using those 53 RecA inhibitors as probes. There were 55 non-inhibitors chosen by 
their structural similarity with those inhibitors using Z cutoff of -0.4. One-fifth of the whole 
dataset were randomly splited as the external validation set, and the rest four-fifth were used 
for model building and selection. The sphere exclusion method, which developed in our 
laboratory, was used to divide each modeling set into multiple training/test set pairs. 
Hundreds of kNN models were generated by using a simulated annealing variable selection 
procedure. All the models were evaluated by Correct Classification Rate (CCR) (equation 3) 
and were selected based on the criteria that both CCRtrain and CCRtest were equal to or higher 
than 0.80. In this case, there were 497 qualified models generated. However, when these 
qualified models were used to predict those external set compounds, the performance of 
CCRexternal for all external compounds reached only 0.48. There were nine RecA inhibitors in 
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total in the external validation set, and six of which were wrongly predicted, representing the 
prediction statistics of the selectivity value being as low as 0.33.  
To further explore the reason why model building achieved with only limited success, 
those 6 RecA  inhibitors were put into the modeling set, with the external validation set 
subsitituted with another six RecA inhibitors randomly chosen from the original modeling set 
compounds. Then, kNN models were generated following the same above procedure 
including Sphere Exclusion protocol and simulated annealing variable selection; however, 
only 22 models qualifed the threshold having both CCRtrain and CCRtest equal to or higher 
than 0.80. Moreover, the statistics of the external set prediction, CCRexternal, by these 
consensus models were greatly improved, achieving 0.84 (compared to 0.48 previously). 
Herein, we observed that the model statistics declined dramatically for the dataset when those 
6 RecA inhibitors presented: qualified model numbers drops considerably when those 6 
compounds were in the modeling set, while CCRexternal was very low when they were in the 
external validation set. Therefore, it was highly suspected that there were some mislabled 
compounds or activity cliff pairs in this version of RecA dataset, which became the apparent 
obstacle for the building of successful kNN-QSAR models..     
4.3.2 Identifications of Compound Pairs with Activity Cliffs and Data Curation 
Tanimoto Coefficient (Tc) values for each pair of compound structures in the first 
version of RecA dataset (53 inhibitors and 55 non-inhibitors) was calculated, followed by the 
conduction of pair-wise comparison. RecA inhibitors and non-inhibitors were first clustered 
using a hierarchical clustering method, and the tree structure was shown on the above and left 
side of the heatmap in Figure 4.2. The color bars below/beside the hierarchical cluster tree 
represented the compound class each structure belonged to: red as RecA inhibitor and green 
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as RecA non-inhibitor. Though most inhibitors were clustered together with inhibitors, and 
most non-inhibitors with were clustered with non-inhibitors, it could still be clearly seen that 
some inhibitors were positioned in close enough proximity with non-inhibitors in the tree, 
which suggested the existence of activity cliffs in the dataset. The center of the heatmap, 
Figure 4.2, showed the pair-wise comparison scores between each structures in the dataset, 
which further confirmed this hypothesis. The right side color bar, from red to yellow to green 
to blue, showed the increasing degrees of structural similarity between compound pairs: the 
more red of each small square, the less similar the compound pairs were, while the more blue 
of it, the more similar the compounds were. While it was commonly known that the diagonal 
of the heatmap should be dark blue: each compound is identical to itself and thus the bluest, 
several other dark blue matricies were noticed in the heatmap. The identification of those 
dark blue matrices unrealed the activity cliffs of several structurally highly similar compound 
pairs (Figure 4.3) as well as some undiscovered duplicates. 
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Figure 4.2. Heatmap of pair-wise Tc analysis for the first version RecA dataset. RecA 
inhibitors (53) and non-inhibitors (55) were first clustered using hierarchical clustering 
method, as shown on the above and left side of the heatmap. The color below the hierarchical 
clustering represents whether the individual compound belongs to the category of either 
inhibitor (red) or non-inhibitor (green). 
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*previously labeled as non-inhibitor. 
 
Figure 4.3. Activity cliffs of RecA inhibitors and non-inhibitors. These four pairs of 
activity cliff compounds were identified by binary classification QSAR models, and were 
further tested again experimentally. Two pairs (B and C) were verified to be true activity 
cliffs. The previously identified non-inhibitors in pairs A and D were found to be weak RecA 
protein inhibitors, with the IC50 being 230µM and 117µM. 
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As shown in Figure 4.3, the backbones of chemical structures within each activity 
cliff group were identical, and the only difference is either absence/presence of a phenolic 
hydroxy or different location of them. The first compound within each group (with asterisk) 
were first labeled as RecA non-inhibitors; however, such small differences usually would not 
render large difference for RecA binding activity. Therefore, we suggested these 4 
compounds to be re-tested in our colaborator‟s lab using the same protocol RecA inhibitors 
were originally identified. The experimental results confirmed two compounds to be true 
activity cliffs with their pair ones (B and C in Figure 4.3), and the other two (A and D in 
Figure 4.3) to be mislabeled false negatives with low RecA binding affinity (> 100 µM). 
These promising results showed that kNN-QSAR models were not only powerful enough to 
identify possible mislabeled compounds, but could also be used to help detect true activity 
cliff compound pairs. 
Our previous experience indicated that the presence of activity cliff compound pairs 
would dramatically decrease the statistics for kNN QSAR model generation as well as 
consensus prediction, therefore, for each pair compounds, we only keep the RecA inhibitors, 
and remove the other RecA non-inhibitors out of the whole dataset. Moreover, for the 
duplicate compound pairs present in the group of both RecA inhibitors and non-inhibitors, 
those labeled as non-inhibitors were removed. Therefore, there were ninie compound in 
RecA non-inhibitors group were removed in total. 
Furthermore, results of additional screened compounds from Boston University, IOC 
and our colaborator‟s lab were added in the first version dataset. After removing duplicate 
chemicals, the second version of RecA dataset were generated, which encompassed 145 
confirmed RecA inhibitors and 26,288 non-inhibitors.  
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4.3.3 QSAR Classification Models On Dataset After Curation 
The RecA dataset size increased a lot after incorporating newly identified RecA 
inhibitors and non-inhibitors from other multiple sources. The RecA inhibitors themselves 
were highly diversified in chemical space, thus presenting a great challenge for QSAR 
modeling. To address it, the hierarchical cluster approach was firstly used to analyse the 
RecA inhibitors dataset, with the results shown in Figure 4. It was clearly seen that the 
cluster dendrogram could be cut into three sub-trees easily, representing three distinct groups 
of RecA inhibitors according to their structural similarity among each other. The largest 
group (group 1) contained 87 RecA inhibitors; the mid-sized group (group 2) had 42; and the 
smallest group (group 3) had only 16 compounds. 
Using the hierarchical clustering, a method of unsupervised learning, before the 
QSAR study of supervised learning shed light on building models on these highly diversified 
dataset. Then, similarity search was performed against RecA non-inhibitors using inhibitors 
in each cluster as probes. There were 113 non-inhibitors chosen by their structural similarity 
with those inhibitors in group 1 using Zcutoff of 1, making the entire dataset of 200 RecA 
inhibitors and non-inhibitors for kNN-QSAR modeling. Similarly, 55 non-inhibitors were 
chosen for 42 RecA inhibitors in group 2, and 19 compounds were chosen for 16 RecA 
inhibitors in group 3. Among these non-inhibitors, only one compound was chosen by both 
group 1 and group 2 probes, representing the non-overlapping chemical structures each group 
of compounds represented.  
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Figure 4.4. Hierarchical clustering of 145 RecA inhibitors. The descriptors for all 145 
RecA inhibitors were calculated by Dragon software, and the hierarchical clustering was 
performed by R. According to the structural similarity of compounds between each other, 
three groups of compounds were clustered. The largest group (group 1) has 87 RecA 
inhibitors; the mid-sized group (group 2) has 42; and the smallest group (group 3) has only 
16 compounds. 
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The five-fold CV approach was employed in each of the three RecA dataset split, so 
that only four-fifth of the dataset compounds were used for model building and selection. 
These modeling sets were then rendered the split of multiple training/test set pairs using the 
Sphere Exclusion technique, and multiple models were generated with simulated annealing 
variable selection approach. All model building statistics were available in Table 1. 
Predictive kNN-QSAR models were sucessfully built in both group 1 and 2. For group 1, 
there were 5,640 models passed the criteria that both CCRtrain and CCRtest equal to or higher 
than 0.80. The number of models that qualifed the same thereshold for group 2 dataset 
exceeded 30,000, so we had to increase the cutoff value for both CCRtrain and CCRtest to 0.9, 
and keep only manageable number of models for consensus prediction. Even for such a high 
criteria, there were still 20,863 models qualifed. However, as for model statistics in group 3, 
less than 20 models were chosen given that both CCRtrain and CCRtest were equal to or high 
than 0.80. There were only 339 models qualifed after the cutoff values were both decreased 
to 0.7, as shown in Table 1. These results from modeling sets suggested that the data quality 
in both group 1 and 2 were good enough to build statistical powerful models, while group 3 
data were not, only yielding many poor models.  
Moreover, models that passed the qualified threshold for both CCRtrain and CCRtest 
were applied to predict RecA inhibitors and non-inhibitors in the external validation sets. 
Consistent with the above hypothesis, models built from group 1 and group 2 were able to 
classify correctly RecA inhibitors from non-inhibitors in the external sets, achieving at least 
0.75 for CCRexternal of group 1 and 0.80 for CCRexternal for group 2; however, the prediction 
statistics for the external set compounds from group 3 were no better than random guesses, 
with the lowest CCRexternal being 0.13.  
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Figure 4.5. Five-fold external set prediction results by kNN-QSAR for RecA dataset 
after cluster. 
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a
: N(1) = number of inhibitors, N(2) = number of non-inhibitors, TP = true positive (inhibitors predicted as inhibitors), FP = false positives 
(non-inhibitors predicted as inhibitors), FN = false negatives (inhibitors predicted as non-inhibitors), TN = true negative (non-inhibitors 
predicted as non-inhibitors), SE = sensitivity = TP/N(1), SP = specificity = TN/N(2), EN - the normalized enrichment, EN(1) = (2TP * 
N(2))/(TP * N(2) + FP * N(1)), EN(2) = (2TN * N(1))/(TN * N(1) + FN * N(2)), and CCR = correct classification rate.  
b
: Models with both CCRtrain and CCRtest over 0.8. 
c
: Models with both CCRtrain and CCRtest over 0.9. 
d
: Models with both CCRtrain and CCRtest over 0.7. 
Table 4.1. Results for the five-fold external sets cross validation as well as the secondary external set (from 
WOMBAT) validation using three different machine learning methods. 
Group of RecA 
inhibitors 
External 
Sets 
Number of 
Models 
Prediction 
CCR 
Confusion Matrix  Statistics 
N(1)
a
 N(2)
a
 TP TN FP FN  SE SP EN(1) EN(2) 
 1 920
b
 0.84 17 23 13 21 2 4  0.76 0.91 1.80 1.59 
 2 945 0.80 17 23 13 19 4 4  0.76 0.83 1.63 1.56 
Group 1 3 622 0.85 17 23 15 19 4 2  0.88 0.83 1.67 1.75 
 4 1629 0.79 18 22 13 19 3 5  0.72 0.86 1.68 1.51 
 5 1524 0.75 18 22 13 17 3 5  0.72 0.77 1.68 1.47 
 1 4377
c
 0.89 7 14 6 13 1 1  0.86 0.93 1.85 1.73 
 2 3630 0.85 10 9 7 9 3 0  0.70 1.0 1.35 2.0 
Group 2 3 4999 0.83 8 11 6 10 2 1  0.75 0.91 1.61 1.76 
 4 3537 0.95 10 9 9 9 1 0  0.90 1.0 1.78 2.0 
 5 4320 0.93 7 12 6 12 1 0  0.76 1.0 1.82 2.0 
 1 13
d
 0.65 2 5 1 4 1 1  0.50 0.80 1.43 1.23 
 2 82 0.13 3 4 0 1 3 3  0.0 0.25 0.0 0.40 
Group 3 3 48 0.59 3 4 2 2 1 2  0.67 0.50 1.45 0.86 
 4 152 0.41 4 3 2 1 2 2  0.50 0.33 0.86 0.80 
 5 44 0.46 4 3 1 2 3 1  0.25 0.67 0.40 1.45 
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Furthermore, the Y-randomization test for each group further confirmed our 
hypothesis.  For both group 1 and group 2, models obtained for the training sets with 
randomized activities had significantly lower values of statistical parameters, such as CCRtrain 
and CCRtest, than the ones with original activity labels. However, for group 3, most QSAR 
models generated in the Y-randomization test exhibit relatively comparable statistics to the 
models generated without randomization, which implied that the QSAR models obtained in 
group 3 dataset were not robust enough. 
4.3.4 Virtual Screening To Identify Putative RecA Inhibitors 
Virtual screening was conducted using the consensus approach, which relies on 
averaging predictions from all qualified models, i.e. all models with both CCRtrain and 
CCRtest equal to or greater than 0.80 instead of using only one single and best model. Since 
the number of total models qualifed was still large, herein, for each cluster of RecA dataset, 
we only used the group of models yielding the highest CCRexternal for the virtual screening. 
An important condition that ensures reliable predictions by the model is the use of AD. 
Therefore, two types of AD were employed in the virtual screening of compound databases, 
which includes a global AD and local AD. The global AD, which acts as a filter, ensures 
some level of global similarity between the predicted compounds and the compounds in the 
modeling set, while the local AD is defined for each of the individual classification models. 
A large external database including around 6,500,000 compounds from the ZINC 7.0 
database, around 59,000 from World Drug Index (WDI) dataset, and 10,000 from TimTec 
Diversity library were screened for putative RecA inhibitors. These original collections had 
many duplicates, such as many salt forms for the same chemical entity, therefore, all 
molecules were firstly “washed” using the Wash Molecules tool in MOE, keeping only the 
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main organic chemical entities. Duplicates were then identified by XChem and were 
removed using MOE. We also removed all compounds included in our modeling and external 
validation sets. Dragon descriptors were generated for the remaining unique compounds in 
the database, which were then subjected to a global AD filter for the modeling set from RecA 
group 1 and group 2 compounds respectively. The Zcutoff of 0.5 was applied because we 
considered the trade off for both the number of compounds chosen for consensus prediction 
and the confidence level we had for our model prediction accuracy. Next, all kNN-QSAR 
models with CCRtrain and CCRtest ≥ 0.80 generated from group 1 RecA dataset were 
employed in consensus fashion to predict those compounds filtered by global AD from group 
1 modeling set; while consensus models generated from group 2 dataset were used to predict 
compounds filtered by group 2 global AD. This resulted in a selection of 1,470 active hits for 
group 1 and 1,662 hits for group 2. kNN-QSAR consensus models were then used as final 
filters for the determination of putative RecA inhibitors. To obtain the higher confidence 
level for each prediction, we took both the consensus score (average class number) and 
model coverage into consideration. In particular, only the hits with average class number 
between 1.0 and 1.25 and the model coverage over 50% were selected. We found that there 
were 12 compounds from ZINC database, 11 from WDI library, and 10 from TimTec 
Diversity library that satisfied both criteria. 
4.3.5 Experimental Validation 
For all computational hits identified by consensus predictions, 11 compounds were 
chosen to be tested experimentally against RecA APTase inhibitory assays by considering 
both commercial availability and their prices. These test chemicals included Cupressuflavone 
from ZINC 7.0 database, Hinokiflavone from the World Drug Index, and nine chemicals (ID: 
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ST025018, ST026920, ST026922, ST044784, ST059022, ST069932, ST029446, ST002554 
and ST072510) from the TimTec Diversity Set 10K. Five of them showed the ATPase 
inhibitory activities against RecA protein, in the range of 5~28 µM. For each tested 
compounds, the full dose-response curve was obtained and the inhibition IC50 was calculated. 
We should emphasize that in our QSAR modeling approaches, only binary endpoints were 
used for generating models and virtual screening, so no estimation of exact binding affinities 
(Ki values) had been made. Consequently, these confirmed experimental results were 
considered very promising. 
  
 
9
4 
Table 4.2. The experimental test for the five computational hits of 5-HT1A inhibitors by mining the TimTec GPCR targeted 
screening library. 
 
Structure 
  
No. 
 
Name 
 
 Source  
library 
 
Most similar compound 
 in modeling set 
 
Tc 
 
kNN-QSAR 
prediction 
score 
 
Exp. IC50 
(µM) 
 
 
 
 
 
1 
 
 
 
 Hinokiflavone 
 
 
 
World 
Drug 
Index 
 
 
 
 
 
1.0 
 
 
 
1.02 
 
 
 
10 
 
 
 
 
 
 
 
2 
 
 
 
 
Cupressuflavone 
 
 
 
 
ZINC 
 
 
 
 
 
 
1.0 
 
 
 
 
1.14 
 
 
 
 
 Non-inhibitor 
 
 
 
 
  
 
3 
 
 
 
 
ST025018 
 
 
 
TimTec 
Diversity 
library 
 
 
 
 
 
 
 
0.65 
 
 
 
 
1.12 
 
 
 
 
Non-inhibitor 
  
 
9
5 
 
 
 
 
 
 
 
4 
 
 
 
 
 
ST026920 
 
 
 
 
TimTec 
Diversity 
library 
 
 
 
 
 
 
 
0.42 
 
 
 
 
 
1.07 
 
 
 
 
 
8.3 
 
 
 
 
 
 
 
 
5 
 
 
 
 
 
ST026922 
 
 
 
 
TimTec 
Diversity 
library 
 
 
 
 
 
 
 
 
 
0.38 
 
 
 
 
 
1.07 
 
 
 
 
 
12 
 
 
 
 
 
6 
 
 
 
ST044784 
 
 
TimTec 
Diversity 
library 
 
 
 
 
 
 
0.53 
 
 
 
1.23 
 
 
 
Non-inhibitor 
 
 
 
 
 
7 
 
 
 
 
ST059022 
 
 
 
TimTec 
Diversity 
library 
 
 
 
 
 
 
 
 
0.41 
 
 
 
 
1.13 
 
 
 
 
Non-inhibitor 
  
 
9
6 
 
 
 
 
 
 
 
8 
 
 
 
 
ST069932 
 
 
 
TimTec 
Diversity 
library 
 
 
 
 
 
 
 
0.33 
 
 
 
 
1.22 
 
 
 
 
Non-inhibitor 
 
 
 
 
 
9 
 
 
 
ST029446 
 
 
TimTec 
Diversity 
library 
 
 
 
 
 
0.76 
 
 
 
1.22 
 
 
 
28 
 
 
 
 
 
 
 
10 
 
 
 
 
ST002554 
 
 
 
TimTec 
Diversity 
library 
 
 
 
 
 
 
 
0.31 
 
 
 
 
1.21 
 
 
 
 
Non-inhibitor 
 
 
 
 
 
 
11 
 
 
 
ST072510 
 
 
TimTec 
Diversity 
library 
 
 
 
 
 
 
0.31 
 
 
 
1.25 
 
 
 
5.3 
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4.4 Conclusions 
Antibiotic resistance is an escalating problem requiring the discovery of novel 
antibiotic classes acting on nonclassical cellular targets. Targeting the nonessential genes, for 
example RecA, offers possible attractive solution. In this study, we have developed 
combinatorial Quantitative Structure-Activity Relationship (QSAR) model for hundreds of 
chemically diverse RecA inhibitors and their structurally similar inactive compounds 
resulting from high-throughput screening and the subsequent confirmatory binding assays. 
The initial attempts to classify 53 RecA inhibitors out of over 3,000 non-inhibitors met with 
only limited success, due to the fact that the activity cliffs exist in several highly similar 
compound pairs identified by pair-wise Tanimoto Coefficient (Tc) analysis. Then, a new 
dataset, containing 145 RecA inhibitors and 26,132 non-inhibitors, was created after both 
data curation of those activity cliff pairs and incorporation of more up-to-date experimental 
testing results. The new dataset was clustered into three groups according to structure 
similarity, then the variable selection k-Nearest Neighbor (kNN), Random Forest (RF) and 
Support Vector Machines (SVM), were employed for model building within each group 
using 2D topological Dragon chemical descriptors. Highly predictive QSAR models were 
generated with leave-one-out cross-validated (LOO-CV) Correct Correlation Rate (CCR) and 
the external CCR values were as high as 0.85, which is greatly improved compared to the 
CCR of 0.79 for model building without clustering. With two differently defined 
applicability domain thresholds, all validated QSAR models were employed concurrently for 
virtual screening (VS) of an in-house compound collection including 9.5 million molecules 
compiled from the ZINC7.0 database, the Word Drug Index (WDI) database, and the TimTec 
Diversity Set. VS resulted in 31 structurally unique consensus hits that were considered novel 
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putative RecA inhibitors. These computational hits had several novel structural features that 
were not present in the original data set.  There were 11 computational hits, some of them 
possessing novel scaffolds, that were tested experimentally and 5 out of 11 were confirmed 
to be active against RecA, with IC50 values ranged 5 ~ 28 µM. In summary, this study 
illustrates the power of the combinatorial QSAR-VS method as a general approach for the 
effective identification of structurally novel bioactive compounds.  
 
  
 
 
  
  
 
CHAPTER 5 
DEVELOPMENT OF COMBINATORIAL QSAR MODELS FOR 5- 
HYDROXYTRYPTAMINE 1A RECEPTOR AND VIRTUAL SCREENING OF 
LIBRARIES WITH DIFFERENT CHARACTERISTICS 
 
5.1 Introduction 
The 5-Hydroxy Tryptamine receptor subtype 1A (5-HT1A) is highly expressed in the raphe 
nuclei region and limbic structures; for that reason 5-HT1A has been an attractive target to 
treat mood disorders such as anxiety and depression. We have developed binary 
combinatorial QSAR models for 5-HT1A binding using data retrieved from the PDSP Ki 
database by employing k Nearest Neighbor (kNN), Random Forest (RF) and Support Vector 
Machine (SVM) prediction methods. We have employed a rigorous model development 
workflow, including extensive internal and external validation. The classification accuracies 
of the models to discriminate 5-HT1A binders from the non-binders were as high as 86% for 
the external test set. These models were used to mine chemical libraries with different 
characteristics, including drug-like libraries from the World Drug Index and Prestwick, 
GPCR-targeted libraries from TimTec and ASINEX, and diversity libraries from TimTec and 
ASINEX. 15 computational hits were tested in radioligand binding assays with a success rate 
of 60%, and one compound was found to be very potent, having a binding affinity of 2.3 nM 
with 5-HT1A. 
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5.1.1 Introduction for the 5- Hydroxytryptamine (serotonin) receptor 1A 
The 5-HT1A receptor is a subtype of 5-HT receptor that binds the endogenous 
neurotransmitter serotonin (5-hydroxytryptamine, 5-HT). It is the most widespread of all the 
5-HT receptors, an important family of G protein-coupled receptors (GPCRs). In the central 
nervous system, 5-HT1A receptors exist in the cerebral cortex, hippocampus, septum, 
amygdala, and raphe nucelus in high densities, while low amounts also exist in the basal 
ganglia and thalamus. It has been among the most important molecular targets that are 
actively being explored for potential drug discovery efforts in psychoactive treatment. 
Because of its dense concentration on cortical and hippocampal pyramidal neurons, 5-HT1A 
receptors have been actively studied in recent years for novel strategies for treating the 
cognitive deficits in schizophrenia. In fact, atypical antipsychotic drugs modestly enhance 
cognition, and several atypical antipsychotic drugs have 5-HT1A partial agonist activity (eg, 
aripiprazole, clozapine, olanzapine, ziprasidone, quetiapine). In addition, 5-HT1A receptor 
agonists, such as buspirone and flesinoxan, show efficacy in relieving anxiety and depression, 
and buspirone and tandospirone are currently approved for these indications in various parts 
of the world. Others, such as gepirone, flesinoxan, flibanserin, and PRX-00023, have also 
been investigated, though none has been fully developed and approved as of yet. Some of the 
atypical antipsychotics, like aripiprazole, are also partial agonists at the 5-HT1A receptor and 
are sometimes used in low doses as augmentations or standard antidepressants, for example, 
the selective serotonin reuptake inhibitors (SSRIs). 
5-HT1A receptors have recently received considerable attention as treatments for 
neurodegenerative diseases. 5-HT1A receptor activation has been shown to increase 
dopamine release in the medial prefrontal cortex, striatum, and hippocampus, and may be 
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useful for improving the symptoms of Parkinson's disease. As mentioned above, some of the 
atypical antipsychotics are 5-HT1A receptor partial agonists, and this property has been 
shown to enhance their clinical efficacy. Enhancement of dopamine release in these areas 
may also play a major role in the antidepressant and anxiolytic effects seen upon postsynaptic 
activation of the 5-HT1A receptor. Moreover, 5-HT1A receptor antagonists such as 
lecozotan have been shown to facilitate certain types of learning and memory in rodents by 
stimulating the release of glutamate and acetylcholine in various areas of the brain. As a 
result, they are being developed as novel treatments for Alzheimer's disease. Taken together, 
there is a critical need in developing novel 5-HT1A receptor modulators to benefit the 
aforementioned diseases. 
5.1.2 Introduction of the Dataset for QSAR Model Building 
The 5-HT1A binders and non-binders were downloaded from the NIMH 
Psychoactive Drug Screening Program (PDSP). By querying in PDSP, 105 unique 
compounds were identified to be 5-HT1A binders. 78 nonbinders were also extracted, which 
were shown to have no binding to the 5-HT1A receptor at 1mM concentration. Most of these 
non-binders shared a relatively high structural similarity with those 105 binders. 
5.1.3 Introduction of the Libraries for Virtual Screening 
5.1.3.1 Drug-like Screening Libraries.  
Drug-like databases are collections of currently marketed drugs or drug candidates in 
the approval process. For our study, we used the World Drug Index (WDI) database as well 
as the Prestwick Chemical Library (PCL).  
  102  
 
WDI is maintained by Derwent Publications and contains 59,000 drugs and 
pharmacologically active compounds, including all marketed drugs. WDI993 also contains 
175,000 synonyms, 73,000 trade names, 26,000 manufacturers, 6700 International Non-
proprietary Names, 8000 US Adopted Names, 17,000 journal and conference references, and 
more, including extensive medical data, such as indications and usage, interactions, adverse 
effects, mechanism of action, and activity keywords. 
PCL is a collection of the Prestwick chemical company. It contains 1,200 small 
molecules with 100% being marketed drugs, thus it represents the greatest possible degree of 
drug-likeliness. The active compounds were selected for their high chemical and 
pharmacological diversity as well as for their known bioavailability and safety in humans. 
5.1.3.2 Targeted Screening Libraries.  
5-HT1A belongs to the big family of GPCR, therefore, GPCR-targeted libraries were 
virtually screened for the purpose of identifying new 5-HT1A ligands. In the study, the 
TimTec AntiTarg-G library and ASINEX Synergy GPCR CNS library were chosen. The 
TimTec AntiTarg-G library is a plated screening set of molecules that contain chemical 
lattices present in compounds reported in the technical or patent literature to possess GPCR-
ligand properties. A pre-filtered diversity collection of 2,300 compounds is assembled which 
provides a high-value screening library of molecules for identifying the new GPCR ligands. 
Moreover, Structural constraints and novel pendants within these lattices provide the 
structural variability to identify new chemical directions for hit optimization.  
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Similarly, the ASINEX Synergy GPCR CNS library is a collection of the ASINEX 
Company and is composed of 3,233 compounds rich in GPCR drug-like pharmacophore 
fragments. 
5.1.3.3 Diversity Screening Libraries.  
The diversity libraries we decided to use are also from TimTec and ASINEX, named 
TimTec Diversity Set 10K and ASINEX Diverse Set-Platinum 5K. The diversity screening 
set from TimTec contains 10,000 samples selected from the company‟s stock of over 
180,000 compounds as the most structurally diverse and competitively priced collection. The 
assorted set stands out as having a diverse selection of singletons identified in the TimTec 
stock pool of readily available compounds. In addition, it is also a compound collection that 
complies with Lipinski Rules of Five. 
ASINEX Diversity Set-Platinum 5K, which contains 5,072 compounds, is an 
assortment of all other ASINEX libraries based on the compounds‟ structural multiplicity. 
The ASINEX Company claimed it to be a great starting point that requires a pure diversity of 
chemicals. 
 
5.2 Methods 
5.2.1 Dataset Curation 
For the purposes of this work, the data was curated following the guidelines our 
laboratory suggested earlier
91
. First, all molecules were cleaned using the Wash 
Molecules module in MOE
8
 (v.2009.10). This software processes chemical structures by 
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carrying out several standard operations including 2D depiction layout, hydrogen 
correction, salt and solvent removal, chirality and bond type normalization (all details can 
be found in the MOE manual
8
). Second, ChemAxon Standardizer
92
 was used to 
harmonize the representation of aromatic rings. Finally, duplicates were detected by the 
analysis of the normalized molecular structures, which contained 75 duplicate 
compounds for 5-HT1A binders and 17 for non-binders (i.e., different salts or isomeric 
states). The functional data for duplicated compounds were verified to be identical, so in 
each case a single example was removed. The curated subset of the original 5-HT1A 
dataset used in this work included 166 unique organic compounds (105 actives and 61 
inactives). All of the details about the dataset are available in the Supporting Information. 
5.2.2 QSAR Modeling and External Validation 
We have followed the rigorous QSAR workflow for model building, validation and 
virtual screening (Figure 1) established in our laboratory 
93
. For classification QSAR 
modeling, it would be ideal to have the balanced ratio between different compound classes in 
the modeling dataset. However, with 105 binders and 61 non-binders, the 5-HT1A dataset 
was imbalanced. In the absence of special statistical treatment, such a ratio would skew the 
prediction accuracy of the classification models. While we do not want to lose any 
information, different weights for 5-HT1A binders and non-binders were employed during 
the modeling process. Furthermore, in order to perform a five-fold external set cross-
validation protocol, the sample set of 166 compounds was divided into five subsets, with one 
subset used for external testing and the other four as model training and internal testing. This 
was repeated five times and a different one-fifth was used for external testing each time. The 
remaining compounds in the four-fifth section, which were considered modeling dataset, 
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were further partitioned into multiple pairs of chemically diverse and representative training 
and test sets of in different sizes, using the Sphere Exclusion approach developed in our 
laboratory earlier 
81, 94
. 
Moreover, the dataset of 69 additional 5-HT1A binders from WOMBAT served as 
independent external validation set. We used models built from 166 5-HT1A binder/non-
binder dataset from PDSP to verify those 69 compounds. We should emphasis that these new 
binders are unique structures from existing PDSP binders. In the consensus prediction 
process, both model prediction values and model overages were taken into consideration. The 
success of this additional external validation would suggest that our QSAR models are 
predictive and robust enough to be applied for virtual screening. 
5.2.3 Virtual Screening of Various Types of Libraries 
As illustrated in the workflow of Figure 1, QSAR models that passed both internal 
and external validation were employed for virtual screening. A global applicability domain 
(calculated using all descriptors) was applied first in order to filter out compounds that 
structurally highly different from the compounds in the modeling set. All 105 known 5-
HT1A binders extracted from PDSP were used as probes in the calculations. Then, the 
consensus prediction of various machine learning methods was only conducted on compunds 
chosen by the global AD. The results were accepted only when the compound was found 
within the applicability domains of more than 50% of all models used in consensus 
prediction and the standard deviation of estimated means across all models was small. During 
the consensus prediction of kNN, we restricted ourselves to the most conservative 
applicability domain for each model using the (cf. Equation 4) Zcutoff = 0.5. 
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The screening was performed on various chemical libraries with different 
characteristics: drug-like databases named the Prestwick Chemical Library 
95
 and the World 
Drug Index (WDI 
96
), GPCR-targeted databases named the TimTec ActiTarg-G (GPCR) 
library 
97
and the ASINEX Synergy GPCR CNS library 
98
, and diversity databases from the 
TimTec Diversity Set 10K 
99
 and the ASINEX Diversity Set-Platinum 5K 
100
.  
All the modeling and virtual screening calculations were done at a 352-processor 
Beowulf Linux cluster of the ITS Research Computing Division of the University of North 
Carolina at Chapel Hill. The compute nodes are Intel Xeon IBM BladeCenter of Dual Intel 
Xeon 2.8GHz, with 2.5GB RAM on each node. The cluster runs the Red Hat Enterprise 
Linux 4.0 (32-bit) and the nodes communicate via a Gigabit Ethernet network. The 
processing speed of QSAR-based screening is relatively high, ca. 100K compounds per 
minute. As could be expected, the processing speed was found to scale linearly with the size 
of the screening library. 
5.2.4 Experimental Testing 
For all virtual hits chosen by consensus predictions of kNN, RF and SVM, 15 
chemicals were further selected including 5 compounds from Prestwick library, 5 from 
TimTec AntiTarg-G library, and 5 from TimTec Diversity Set 10K. These structurally 
diverse and commercially available hits were purchased from different suppliers and 
experimentally tested in PDSP in 5-HT1A radioligand binding assays. 
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5.3 Results 
Overall, Dragon produced over 2,000 different descriptors. Most of these descriptors 
characterize chemical structure, but several depend upon the arbitrary numbering of atoms in 
a molecule and are introduced solely for bookkeeping purposes. In our study, only 880 
chemically relevant descriptors were initially calculated and 672 descriptors were eventually 
used for 5-HT1A binding dataset after deleting descriptors with zero value or zero variance. 
Dragon descriptors were range-scaled prior to distance calculations since the absolute scales 
for Dragon descriptors can differ by orders of magnitude
101
. Accordingly, our use of range-
scaling avoided giving descriptors with significantly higher ranges a disproportional weight 
upon distance calculations in multidimensional Dragon descriptor space. 
5.3.1 QSAR Classification Models 
The kNN QSAR method with variable selection afforded multiple models with 
optimal accuracy characterized as CCR for both training and test sets. In total, there were 838 
models with both CCRtrain and CCRtest equal to or higher than 0.80. Most models with CCRtest  
≥ 0.80 also had corresponding CCRtrain ≥ 0.80, but the opposite was not always true. The 
models with high values of both CCRtrain and CCRtest (≥ 0.80) were considered acceptable 
and were selected for consensus prediction. The CCRtrain and CCRtest were found to be as 
high as 0.91 and 0.99, respectively, which implies that the models could correctly identify 51 
binders out of 55 and 34 out of 38 binders (SE = 0.93, SP = 0.89, EN(1) = 1.80, and EN(2) = 
1.85) in the training set and almost all binders and non-binders in the test set. This 
remarkably high internal accuracy and the large number of acceptable models imply that the 
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kNN classification method was generally successful in correctly distinguishing binders vs. 
non-binders using Dragon chemical descriptors. 
5.3.2 QSAR Model Validations 
In addition to the internal validation of kNN, RF and SVM models using test sets, Y-
randomization and external validation are the critical steps of the entire QSAR workflow 
(Figure 1). Only models that have been validated by these two steps can be utilized for 
external prediction and virtual screening 
48
. 
5.3.2.1 Y-randomization Test  
In this Y-randomization test, the binary annotations of 5-HT1A as binders or non-
binders were randomly shuffled, and kNN, RF and SVM classification models were built 
with the same parameter settings. The test was performed once for each training/test set split 
and all runs of Y-randomization tests showed that almost all models had both CCRtrain and 
CCRtest less than 0.70. Moreover, the one-tail hypothesis was applied, and the Z score of 2.17 
was calculated given the non hypothesis of QSAR models for the actual dataset being not 
significantly better than random models. After comparing this Z score with the tabular 
critical values of Zc at different levels of significance (α)
60
, we concluded that with 98.48% 
confidence the null hypothesis H0 should be rejected, and then confirmed that the difference 
of CCRtrain before and after Y-randomization was significant. 
5.3.2.2 External Cross Validation  
The five-fold cross validation approach was employed for external prediction, i.e. the 
33 compounds randomly excluded from modeling set for each fold. Consensus predictions 
were carried out using those predictive models with CCRtrain and CCRtest greater than 0.8 
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under different Zcutoff values (Zcutoff = 0.5 ~ 3.0, Table 1). For Random forest and Support 
vector machine, exactly the same five-fold external sets were implied for validation, and the 
prediction results were compared and summarized in Table 2. Because of the applicability 
domain inherent to individual kNN QSAR models, the consensus prediction usually cannot 
cover the whole dataset, i.e., one binder in the first external set cannot be predicted by 
consensus models using Zcutoff = 0.5. Table 1 shows the consensus scores for each of the five 
fold external sets. The consensus score, in terms of the average class number in classification 
QSAR, was calculated by the fraction of models that predicted a compound as non-binder 
over the total number of models used for prediction plus 1. Under Zcutoff = 0.5, most of the 
external validation set achieved a rather high prediction accuracy. For the forth external set 
split, the prediction achieved 95% for binders and 77% for non-binders, leading to CCRevs = 
0.86. Those falsely predicted binders (average class number > 1.5) were within an 
applicability domain of a small portion of all models, i.e., the model coverage was very low 
and the prediction value is no larger than 1.67. In general, the prediction with such a low 
coverage is viewed as a low confidence level. The higher Zcutoff significantly raised the model 
coverage for binder and non-binder predictions because of the extended applicability domain 
for individual models. However, the prediction with extended applicability domain for 
consensus models also comes with lower confidence level. Generally speaking, in order to 
have reliable and accurate predictions, one has to have a broader model coverage and a 
smaller Zcutoff value. 
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Figure 5.1. The statistics of five-fold external validations of 5-HT1A compounds from 
PDSP for three QSAR methods and Y-Randomization test. 
  
 
1
1
1
 
 
a
: N(1) = number of binders, N(2) = number of non-binders, TP = true positive (binders predicted as binders), FP = false positives (non-binders 
predicted as binders), FN = false negatives (binders predicted as non-binders), TN = true negative (non-binders predicted as non-binders), SE = 
sensitivity = TP/N(1), SP = specificity = TN/N(2), EN - the normalized enrichment, EN(1) = (2TP * N(2))/(TP * N(2) + FP * N(1)), EN(2) = 
(2TN * N(1))/(TN * N(1) + FN * N(2)), and CCR = correct classification rate. 
b
: Some N(1) binders of and N(2) non-binders were out of application domain of all consensus models, thus having no prediction. Only data for 
compounds found within the AD were used for statistical summaries. 
Table 5.1. Results for the five-fold external sets cross validation as well as the secondary external set () validation 
using three different machine learning methods. 
Machine Learning 
Methods 
External Sets 
Prediction 
CCR 
Confusion Matrix  Statistics 
N(1)
a
 N(2)
a
 TP TN FP FN  SE SP EN(1) EN(2) 
 1 0.86 19b 14 18 11 3 2  0.90 0.79 1.62 1.77 
 2 0.61 20 13 15 6 7 5  0.75 0.46 1.16 1.30 
k-Nearest Neighbor 3 0.77 22 11 20 7 4 2  0.91 0.64 1.43 1.75 
 4 0.86 20 13 19 10 3 1  0.95 0.77 1.61 1.88 
 5 0.68 23 10 22 4 6 1  0.96 0.40 1.23 1.80 
 WOMBAT 0.94 69 0 65 NA NA 4  0.94 NA NA NA 
 1 0.80 20 14 16 11 4 3  0.80 0.79 1.47 1.70 
 2 0.68 20 13 15 8 5 5  0.75 0.62 1.32 1.42 
Random Forest 3 0.84 22 11 21 8 1 3  0.95 0.73 1.83 1.68 
 4 0.74 20 13 19 7 1 6  0.95 0.54 1.85 1.28 
 5 0.83 23 10 22 7 1 3  0.96 0.70 1.81 1.69 
 WOMBAT 0.94 69 0 65 NA NA 4  0.94 NA NA NA 
 1 0.87 20 14 19 11 1 3  0.95 0.79 1.86 1.68 
 2 0.68 20 13 18 6 2 7  0.90 0.46 1.71 1.14 
Support Vector 
 
3 0.95 22 11 22 10 0 1  1.00 0.91 2 1.90 
Machine 4 0.76 20 13 18 8 2 5  0.90 0.62 1.71 1.42 
 5 0.76 23 10 21 6 2 4  0.91 0.60 1.64 1.55 
 WOMBAT 0.96 69 0 66 NA NA 4  0.96 NA NA NA 
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In summary, 258 models with CCRtrain, CCRtest and CCRevs equal to or greater than 
0.80 could be applied for consensus prediction and virtual screening. The models chosen for 
the prediction had relatively small Zcutoff (= 0.5) and relatively broad coverage for compounds 
in external datasets (>= 50%). 
5.3.2.3 Independent External Prediction  
We used models built from 166 5-HT1A binder/non-binder dataset from PDSP to 
verify the 69 5-HT1A binders from WOMBAT. We should emphasis that these new binders 
are unique structures from existing PDSP binders. Among the 69 binders (all were within the 
applicability domain), 65 were accurately annotated by kNN consensus prediction (CCRex = 
0.94, Table 1). Thus, the majority of ligands were predicted correctly by our consensus 
models. Since the 4 falsely predicted 5-HT1A binders by kNN had the prediction values 
greater than 1.67, and were within the applicability domain of only 70 models (i.e., 
approximately 30% of all models), the kNN prediction is considered as of low confidence. 
When RF and SVM were applied, the prediction accuracy for the additional 69 binders from 
WOMBAT was also high, ranging from CCRex = 0.94 to 0.96 (Table 1). The success of this 
additional external validation suggested that our QSAR models would be predictive and 
robust enough to be applied for virtual screening. 
5.3.2.4 QSAR Models based Virtual Screening 
Instead of using only one single and best model for virtual screening, the consensus 
prediction approach was applied. To perform the consensus prediction, we averaged 
predictions from all qualified models, i.e. 258 models with both Internal and External 
CCRtrain and CCRtest equal to or greater than 0.80 from kNN, 7 models (same criteria) from 
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Random Forest (RF) and 62 from Support vector machine (SVM). Models generated by the 
modeling set yielding the highest CCRevs (for the third split of five-fold CV) were used for 
the virtual screening. Initially, 55,384 compounds from the Prestwick Chemical Library 
(PCL) and World Drug Index (WDI) dataset were screened for 5-HT1A binding, and the 
numbers of compounds chosen by AD within different Zcutoff were shown in Figure 4. The 
compounds within Zcutoff 0.5 were further predicted by kNN consensus models. 234 
compounds from Prestwick were predicted as binders by at least one of the kNN consensus 
models. To narrow the hit list and obtain the higher confidence level for each prediction, we 
took both the consensus score (average class number) and model coverage into consideration. 
In particular, only the hits with average class number between 1.0 and 1.1 and the model 
coverage over 50% were selected. We found 125 compounds from Prestwick and 181 from 
WDI satisfied both criteria. 
However, the majority of these virtual hits were highly similar to the compounds 
already known (compounds in the QSAR modeling set), so it would be least attractive to test 
these hits experimentally. To verify the diversity of those virtual hits, pairwise similarity 
calculations were performed. Each compound was represented by a fingerprint of 166 
substructure keys (MACCS structural keys
102
), indicating the presence or absence of a 
particular chemical substructure. The pairwise similarity was measured by using the 
Tanimoto coefficients (Tc) to compare the Prestwick virtual hits versus themselves, 
Prestwick virtual hits versus each hit‟s nearest neighbor from the binders in the modeling set 
(identified by Dragon descriptors and Euclidean distances), Prestwick virtual hits versus the 
binders used in model building, and the binders used in model building versus themselves. 
The majority of compound pairs between Prestwick virtual hits versus each hit‟s nearest 
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neighbor within the modeling set have Tc over 0.9, while other pair-wise similarity scores 
show a normal distribution, suggesting that the virtual hits are structurally highly similar with 
our already known 5-HT1A binders (Figure 5).  
To explore more structurally diverse 5-HT1A compounds, we further screened 
GPCR-targeted libraries and diversity libraries from the commercial chemical sources of 
both TimTec and ASINEX. Therefore, the additional collection of 24,000 compounds were 
screened, which includes the TimTec ActiTarg-G (GPCR) library of about 2,300 compounds, 
the ASINEX Synergy GPCR CNS library of about 7,000 compounds, the TimTec Diversity 
Set 10K of 10,000 compounds and the ASINEX Diversity Set-Platinum 5K of about 5,100 
compounds. By applying various AD, the putative hit rate for different screening libraries 
within various Zcutoff values was shown in Figure 4, and the exact numbers of compounds 
chosen from them were also available in supplementary material (Table S1). It is obvious 
that many more chemicals were selected from the GPCR library than the diversity library by 
applying the same Zcutoff value, verifying that the diversity library has much more structural-
varied compounds compared with our modeling set than the GPCR-targeted library. 
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Figure 5.2. The PCA plot of three virtual screening libraries and modeling set 
compounds. Chemical compounds in modeling set are labeled red; Chemical compounds in 
Prestwick library are labeled green; Chemical compounds in TimTec AntiTarg-G library are 
labeled blue; Chemical compounds in TimTec Diversity Set 10K are labeled orange.  
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Figure 5.3. Hit rate of 5-HT1A binders on diverse screening libraries using different 
Zcutoff values.   
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The compounds within Zcutoff 0.5 were further predicted by kNN consensus models. 
445 compounds from the TimTec ActiTarg-G library, 487 from the TimTec Diversity Set 
10K, 2,177 from the ASINEX Synergy GPCR CNS library and 782 from the ASINEX 
Diversity Set-Platinum 5K were predicted as binders by at least one of the kNN consensus 
models. To narrow the hit list and obtain the higher confidence level for each prediction, both 
the consensus score and model coverage were taken into account. In particular, only the hits 
with average class numbers between 1.0 and 1.1 and the model coverage over 50% were 
selected. We found that there were 64 compounds from the TimTec AntiTarg-G library and 
40 from the TimTec Diversity Set 10K that satisfied both criteria. As for ASINEX libraries, 
there were still hundreds of compounds that met those strict criteria, so we will not take those 
into consideration at this time. 
Several structural classes were observed by screening different libraries according to 
the Tanimoto coefficients (Tc) values. Notably, many of the 64 virtual hits from the TimTec 
AntiTarg-G library were found to be structurally similar to binders used in model building, 
while the 40 virtual hits from the TimTec Diversity Set 10K displayed highly different 
structural profiles. The pairwise similarity measured by Tc values was also compaired 
between virtual hits versus virtual hits, hits versus their nearest neighbor within the modeling 
set compounds, virtual hits versus modeling set compounds, and modeling set compounds 
versus themselves (Figure 5). It is clearly seen that the virtual hits from the TimTec 
AntiTarg-G library showed structural profiles with a much lower similarity to the known 5-
HT1A binders than Prestwick virtual hits. The average Tc value between TimTec Anti-Targ-
G library hits and their nearest neighbors in the modeling set was 0.6 compared to 0.9 for the 
hits screened from Prestwick. For our virtual hits screened from the TimTec Diversity Set 
  118  
 
10K, the Tc value between hits and their nearest neighbors in modeling set is as low as 0.45, 
suggesting that they are highly structurally different. While these hits are also predicted to be 
5-HT1A binders with a high confidence by our consensus models as well as random forest 
and support vector machine, it would be interesting and exciting to test them experimentally, 
in hope of revealing new scaffold of 5-HT1A binders.   
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Figure 5.4. The structural similarity analysis of virtual hits screened from different 
libraries.  
A: Tanimoto Coefficient (Tc) between Prestwick virtual hits and themselves (Aa), 
Prestwick virtual hits and modeling set compounds (Ab), and Prestwick virtual hits and 
their nearest neighbor compounds in the modeling set (Ac). B: Tc between TimTec 
AntiTarg-G library virtual hits and themselves (Ba), Target library virtual hits and 
modeling set compounds (Bb), and Target library virtual hits and their nearest neighbor 
compounds in the modeling set (Bc). C: Tc between TimTec Diversity library virtual hits 
and themselves (Ca), Diversity library virtual hits and modeling set compounds (Cb), and 
Diversity library virtual hits and their nearest neighbor compounds in the modeling set (Cc). 
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For all virtual hits chosen by kNN, 15 chemicals were further selected for 
experimental testing, including 5 compounds from Prestwick library, 5 from TimTec 
AntiTarg-G library, and 5 from TimTec Diversity Set 10K. The following criteria were met 
when selection was performed: 1) High confidence of consensus prediction by RF and SVM; 
2) Low structural similarity between hits and the 5-HT1A binders we already known; 3) 
Convenient commercial availability. 
5.3.2.5 Experimental Validation 
The validations on our in silico hits by the NIMH PDSP were satisfying and yielded 
many true hits as 5-HT1A binders. We should stress that only binary QSAR models were 
used for screening so no estimate of exact binding affinities (Ki values) had been made. Nine 
out of fifteen in silico hits have the percentage of inhibition at or higher than 50% (i.e. 
Mesoridazine, Clozapine, Risperidone and Fluphenazine from PCL; ST030580 from GPCRs 
targeted library; ST023860, ST074311 and ST057540 from diversity library) and six of them 
even higher than 95%. For these compounds, the IC50 values were obtained from non-linear 
regression of radioligand competition binding isotherms, from which the final Ki (nM) values 
were calculated using the Cheng-Prusoff equation. The five in silico hits from PCL showed 
the highest success rate (80%), though most of them were similar to the modeling set 
compounds (Tc ranged from 0.80 to 0.99, with an average Tc value of 0.86) and no novel 
core scaffolds were found. They were also found to be less interesting from the point of view 
of drug repurposing. Mesoridazine and fluphenazine belong to the typical antipsychotics 
while clozapine and risperidone are atypical antipsychotics; all four compounds had been 
employed in the treatment of schizophrenia and bipolar disorder in clinics.  
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To our surprise, only one in silico hit from the GPCRs targeted library had been 
proved to be active (Ki = 243.8 nM). This compound, ST030580, showed quite different 
rings arrangement from its nearest neighbor in the modeling set while maintaining the 
azaspiro-bicyclic structural element. Among the three confirmed hits from the TimTec 
Diversity Set 10K, compound ST057540 (also known as Lysergol ([(8α)-6-methyl-9,10-
didehydroergolin-8-yl]methanol)) yielded 98.20% binding inhibition against 5-HT1A 
receptor and its Ki value is 2.3 nM (Figure 6). Furthermore, the Tc between this compound 
and its nearest neighbor in the modeling set (ID: 27405, with dibenzo[de,g]quinolone 
structure) is only 0.69, indicating the structural distinctions in general. Lysergol is an alkaloid 
of the ergoline family that occurs as a minor constituent in some species of fungi, and is 
sometimes utilized as an intermediate in the manufacturing of some ergoloid medicines (e.g., 
nicergoline). This compound qualifies for all of the “Lipinski Rule of Five”, with a LogP 
value of 1.76
103, 104
, which is considered to be ideal for both oral absorption and CNS 
penetration. It was also predicted to have very low probability of rapid biodegradation by 
EPI-Suite
105, 106
. Lysergol does not have a known pharmacological action or a precursor 
relationship to LSD, and its pharmacological indication remained to be further explored. Two 
other active hits, compounds ST023860 and ST074311, also show relatively different 
scaffolds in comparison to modeling set compounds with Tc of 0.75 and 0.69 respectively. 
The findings were encouraging and some novel scaffolds identified are currently under patent 
application.  
  
  122  
 
 
Figure 5.5. The full dose response curves for hit compounds and the positive control. Hit 
compounds ST057540 (Ki = 2.3 nM) and ST074311 (Ki = 8,194 nM) are represented in red 
and blue triangles, and the positive control, Methysergide (Ki = 26 nM), is in black squares. 
The full dose response curves show the results in human 5-HT1A receptor radioligand 
binding assay, with [
3
H]-8-OH-DPAT used as the radioligand at the concentration of 0.5 nM 
in the standard binding buffer. 
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In summary, the above results once again proved the predictive power of our binary 
kNN, RF and SVM classification QSAR models built from 5-HT1A binders/non-binders. 
These studies illustrate that the validated QSAR workflow, as employed in this paper, could 
be used as a general tool for identifying promising hits by the means of virtual screening of 
various types of chemical libraries. 
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Table 5.2. The experimental test for the ten virtual hits of 5-HT1A binders identified by virtual screening. 
 
Structure 
  
No. 
 
Name or 
ID 
 
 Source  
library 
 
Most similar compound 
 in modeling set 
 
Tc 
 
kNN 
score 
 
RF 
score 
 
 
SVM 
score 
Percent 
of 
inhibition 
 
Exp. IC50 
(nM) 
  
 
 
1 
 
 
 
Mesoridazine 
 
 
 
 
Prestwick 
library 
 
 
 
 
 
0.80 
 
 
 
1.01 
 
 
 
1.06 
 
 
 
1.00 
 
 
 
> 95% 
 
 
 
33.1 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
 
SKF-75670 
 
 
Prestwick 
library 
 
 
 
 
 
0.80 
 
 
1.02 
 
 
1.04 
 
 
1.00 
 
 
N/A 
 
 
> 10,000 
 
 
 
 
 
 
 
 
 
 
3 
 
 
 
Clozapine 
 
 
 
 
Prestwick 
library 
 
 
 
 
 
0.83 
 
 
 
1.04 
 
 
 
1.07 
 
 
 
1.00 
 
 
 
> 95% 
 
 
 
104.8 
 
 
 
 
4 
 
 
Risperidone  
 
 
 
 
Prestwick 
library 
 
 
 
 
0.99 
 
 
1.00 
 
 
1.02 
 
 
1.00 
 
 
N/A 
 
 
427.5 
 
  
 
1
2
5 
 
 
 
 
 
5 
 
 
 
Fluphenazine  
 
 
 
 
Prestwick 
library 
 
 
 
 
 
0.89 
 
 
 
1.00 
 
 
 
1.13 
 
 
 
1.00 
 
 
 
> 95% 
 
 
 
145.7 
 
 
 
 
 
 
 
 
 
6 
 
 
 
ST016950 
 
 
TimTec 
GPCR 
Targeted 
library 
 
 
 
 
 
0.66 
 
 
 
1.07 
 
 
 
1.10 
 
 
 
1.00 
 
 
 
5.5%
a
 
 
 
 
N/A 
  
 
 
 
7 
 
 
 
 
ST014829 
 
 
TimTec 
GPCR 
Targeted 
library 
 
 
 
 
 
 
 
0.73 
 
 
 
 
1.06 
 
 
 
 
1.27 
 
 
 
 
1.00 
 
 
 
 
39.20% 
 
 
 
 
N/A 
  
 
1
2
6 
 
 
 
 
8 
 
 
ST007472 
 
TimTec 
GPCR 
Targeted 
library 
 
 
 
 
0.76 
 
 
1.03 
 
 
1.09 
 
 
1.00 
 
 
21.80% 
 
 
N/A 
  
 
 
9 
 
 
 
ST030580 
 
TimTec 
GPCR 
Targeted 
library 
 
 
 
 
 
0.84 
 
 
 
1.02 
 
 
 
1.09 
 
 
 
1.00 
 
 
 
95.50% 
 
 
 
243.8
a
 
  
 
 
10 
 
 
 
ST041900 
 
TimTec 
GPCR 
Targeted 
library 
 
 
 
 
 
 
0.74 
 
 
 
1.07 
 
 
 
1.09 
 
 
 
1.00 
 
 
 
4.70% 
 
 
 
N/A 
  
 
1
2
7 
  
 
 
11 
 
 
 
ST023860 
 
 
TimTec 
Diversity 
Set 10K 
 
 
 
 
 
 
0.75 
 
 
 
1.02 
 
 
 
1.12 
 
 
 
1.00 
 
 
 
95.60% 
 
 
 
159.0 
  
 
12 
 
 
ST007110 
 
TimTec 
Diversity 
Set 10K 
 
 
 
 
 
0.84 
 
 
1.08 
 
 
1.14 
 
 
1.06 
 
 
11.10% 
 
 
N/A 
  
 
 
13 
 
 
 
ST074311 
 
 
TimTec 
Diversity 
Set 10K 
 
 
 
 
 
 
0.69 
 
 
 
1.10 
 
 
 
1.14 
 
 
 
1.00 
 
 
 
70.80% 
 
 
 
6261.0 
 
 
Patent under application 
 
 
14 
 
 
ST057540 
 
TimTec 
Diversity 
Set 10K 
 
 
 
 
 
0.69 
 
 
1.05 
 
 
1.14 
 
 
1.00 
 
 
98.20% 
 
 
3.4 
  
 
1
2
8 
  
 
 
15 
 
 
 
ST066677 
 
 
TimTec 
Diversity 
Set 10K 
 
 
 
 
 
0.53 
 
 
 
1.06 
 
 
 
1.13 
 
 
 
1.00 
 
 
 
49.60% 
 
 
 
N/A 
 
a
: The full IC50 curve was generated in further experiment and the Ki value was determined. 
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5.4 Discussions 
We should emphasize that our model validation is a critically inherent feature of our 
QSAR modeling workflow. This issue of model validation had been given a lot of attention 
by the QSAR research community 
107
. Until recently, most practitioners merely presumed 
that internally cross-validated models built from available training set data should be 
externally predictive. We and others have demonstrated that internal validation techniques 
such as leave-one-out (LOO) or even leave-many-out (LMO) cross-validation applied to the 
training set is insufficient to ensure the external predictive power of QSAR models 
15, 48
. 
Thus, we used five-fold cross external validation sets in this study as well as the Y-
randomization test to ensure the robustness and predictive power of kNN models. Needless to 
say, the use of externally validated models and applicability domains is especially critical 
when the models are employed in virtual screening. 
Another important feature of many current biomolecular datasets, especially those 
generated as a result of High Throughput Screening (HTS), is the imbalance between 
“actives” and “inactives.” While in this study there are more actives, in many other cases 
instances of inactives will predominate; for example, the hit rates in assays deposited in 
PubChem by the NIH screening centers forming the Molecular Library Screening Center 
Network (MLSCN) are very low, in most cases not exceeding 0.5% 
108
. The imbalanced 
datasets pose a significant problem for classification QSAR modeling because models that 
correctly predict the same fraction of objects in each class will have different objective 
function values. To circumvent this problem in this study, we assigned different weights of 
objective functions to the underrepresented class (non-binders) versus the other one (binders) 
for model building. The classification models built for the unbalanced subset with different 
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weight objective functions were shown to predict compounds in this external dataset as 
binders versus non-binders with very high accuracy. 
Moreover, another unique 69 5-HT1A binders from different resources (i.e. 
WOMBAT database) were further validated by our consensus models for independent 
external validation. All three QSAR methods (kNN, RF and SVM) can accurately annotate 
the majority of compounds, with CCRex ranged from 0.94 to 0.96. This additional 
independent external validation proposed in our study is unique, and has not yet been used 
elsewhere before. The success of this approach strongly suggested our QSAR models to be 
predictive, robust, and ready for virtual screening. 
Finally, model-based virtual screening was performed on various databases with different 
characters, including two drug-like libraries, two GPCR-targeted libraries, and two diversity 
libraries. Both the global similarity search (using AD) and the subsequent QSAR model 
predictions confirmed our expectations that drug-like libraries and GPCR-targeted libraries 
had a much higher hit rate than diversity libraries, when the same cutoff values were applied, 
though the reason why ASINEX libraries had an extraordinarily high hit rate remained 
unclear. When prediction of QSAR models were made and the pairwise similarity analysis 
was further performed, it once again confirmed our hypothesis that those virtual hits from 
drug-like libraries had much higher structural similarity with our modeling set compounds 
than hits from GPCR-targeted libraries and diversity libraries. After experimental validation, 
60% of the compounds suggested by our QSAR models were confirmed to be 5-HT1A 
binders; however, it was interesting to know that the experimental hit rate of the diversity 
library is much higher than the GPCR-targeted library, and the most potent 5-HT1A binder 
(inhibitor) was screened from diversity library, sharing a very low structural similarity with 
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5its nearest neighbor compound in the modeling set. These interesting findings verified that 
model-based virtual screening outperformed the simple similarity search, and also challenged 
our conventional opinions about structure-activity relationships (SAR), suggesting that it is 
not always true that more similar structures will lead to more similar chemical properties. 
Moreover, it is once again confirmed that by taking the advantage of various computational 
tools, such as QSAR modeling, more novel compounds could be revealed with diverse 
scaffolds. 
5.5 Conclusions 
Our studies demonstrate that classification QSAR models built with Dragon 
descriptors can accurately differentiate true 5-HT1A binders from non-binders. A special 
QSAR modeling scheme was employed for this imbalanced dataset and the models were 
rigorously validated using both internal (multiple training/test set divisions and Y-
randomization) as well as external (five-fold cross external validation sets) validation 
approaches. We have demonstrated that this strategy afforded multiple QSAR models with 
high internal and external predictive power. As part of our QSAR modeling workflow, the 
predictors were further utilized for mining the WOMBAT hits (69 literature extracted 
compounds tested for 5-HT1A binding). We found that our validated models agreed highly 
with the experimental annotation of 69 compounds as 5-HT1A binders as reported in various 
literatures (extracted through WOMBAT database). On the other hand, our models used in 
the most conservative way (i.e., in consensus fashion and with the strictest applicability 
domain criteria) did identify 43 putative 5-HT1A binders among the TimTec AntiTarg-G 
library and TimTec Diversity Set 10K. Ten of them were tested experimentally in Dr. Roth‟s 
lab at UNC and all showed inhibition activities at a single concentration for percentage of 
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inhibition. Interestingly, the five virtual hits identified from the TimTec Diversity Set 10K 
showed higher 5-HT1A binding affinity than the other five from the TimTec AntiTarg-G 
library. One compound (compound ST057540) was found to have the highest Ki of 2.3nM, 
while the Tanimoto coefficients between this compound and its nearest neighbor in the 
modeling set (ID: 27405) was as low as 0.52. The results of our studies suggest that at least 
in some cases when a sufficient amount of data on true binders vs. nonbinding compounds is 
available,  QSAR modeling approaches could be used successfully to complement (and 
possibly educate based on QSAR model interpretation) the conventional scoring functions 
used in three-dimensional docking studies. Furthermore, as we have demonstrated in this 
paper, QSAR models can be successfully used not only to discriminate binders vs. non-
binders but most importantly, for finding promising hits by the means of virtual screening of 
chemical libraries. 
The heatmap of the self-similarity matrix for 5-HT1A modeling set, distributions of 
models for Y-randomization tests, experimental data of 5-HT1A screening hits binding 
affinities, chemical structures and pIC50 values for 5-HT1A modeling dataset and screening 
hits, purity data for target compounds, and others supplementary data indicated in the text are 
available in the Appendix section. 
  
  
 
CHAPETER 6 
SUMMARY AND FUTURE DIRECTIONS 
Combinations of structure-based and ligand-based approaches are being used to assist 
the medicinal chemists in identifying and designing ligands that could pharmacologically 
modulate the target of interest. Computer-Aided Drug Design methods can be categorized 
based on whether the three-dimensional (3D) structure of the target protein is available. If a 
crystal structure of target protein or receptor is accessible, structure-based drug design 
approaches, such as de novo design, docking-scoring, structure-based pharmacophoric search, 
could be used. Those compounds with high structural and physic-chemical 
complementarities to the active site are ranked according to their scores prioritized for 
experimental tests. If the structure of the target protein is not known, which is a more 
common case, ligand-based drug design methods are used, which only relies on knowledge 
of other molecules that bind to the biological target of interest. In this case, the chemical 
structures (m molecules) are represented by strings of numeric characters calculated by 
different types of descriptors (n descriptors). The generated m×n matrix is then analyzed by 
diverse data analysis approaches to predict new molecules.  
Many methods for multi-target predictions mainly consider of the computational 
efficiency; however, when simple similarity search is used for modeling, with the aim of fast 
prediction, the prediction accuracy cannot always be achieved at the same time. This feature, 
alternatively, is the most important aspect about which researches should care. Furthermore, 
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most current approaches of ligand-based drug discovery mainly focus on optimizing the 
computational algorithms to improve the efficiency and/or accuracy of virtual screening; 
however, the success of ligand-based drug design relies not only on the effectiveness and 
robustness of the underlying algorithms, but much more importantly, on the quality of the 
data for model building. Although numerous chemical probe databases have emerged 
recently, seldom evaluation of data quality and reliability was performed. 
6.1 Summary and Future Directions of Chapter 2 
In this chapter, various state-of-the-art data analysis tools in cheminformatics for 
predicting compounds‟ biological properties are introduced. For supervised statistical 
learning, QSAR methods are discussed, including diverse algorithms such as kNN, RF and 
SVM. The concept of applicability domains and external validation tests is also covered. For 
the unsupervised statistical learning techniques, the underlying algorithms for two multi-
profile prediction approaches, the Similarity Ensemble Search (SEA) and Prediction of 
Activity Spectra for Substances‟ (PASS) are introduced. These methods have been 
intensively compared by 7 cases of biological receptors, in terms of both internal recovery 
rate as well as external prediction accuracy. 
The results showed that the internal recovery rate of SEA was about or less than 60%, 
while QSAR always achieved 100%. For external compounds‟ prediction, the results further 
highlighted the use of QSAR over the SEA prediction method. SEA can only predict less 
than half of the external validation set compounds, while QSAR achieved almost 100% for 
the three GPCR targets. PASS has been validated to have moderate prediction accuracy, both 
for internal recovery rate and external prediction accuracy. 
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For future works, more biological targets besides GPCR receptors will be tested for 
the comparison of these three methodologies. Moreover, the server for multi-target QSAR 
prediction is aimed to launch, when more readily developed QSAR models become available. 
6.2 Summary and Future Directions of Chapter 3 
The Molecular Libraries Program (MLP), a NIH Roadmap Initiative, aims to enhance 
chemical biology data through High Throughput Screening (HTS) to obtain chemical probes 
effective at modulating specific biological processes or disease states. PubChem is an open-
access data repository system, acting as the portal site for MLP. To evaluate the quality of 
some biological activities deposited in PubChem, we have conducted in silico modeling 
studies for 5-Hydroxytryptamine Receptor Subtype 1A (5-HT1A) ligands. Our studies 
demonstrated that classification QSAR models can accurately differentiate true 5-HT1A 
binders from non-binders in reliable data sources, such as PDSP and WOMBAT. By contrast, 
we failed to generate qualified models using datasets deposited in PubChem (PubChem 
Assay id (AID) 613, 718, 755). The combinatorial QSAR modeling scheme is employed for 
all three 5-HT1A datasets and the models are rigorously validated using both internal 
(multiple training/test sets, Y-randomization test) as well as external (five-fold cross 
validation) validation. We have demonstrated that this strategy afforded QSAR models with 
high internal and external predictive power. Moreover, the predictors are further utilized for 
cross-validation of the 5-HT1A datasets from different sources. We find that the prediction 
results of our validated models highly agree with the experimental annotation of 69 5-HT1A 
binders as reported in WOMBAT database. Furthermore, the nine PubChem binders, which 
were identified by cross-validated QSAR models as false positive, were sent for experimental 
testing. The experimental results showed 100% agreement with our models‟ consensus 
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predictions, and confirmed that those compounds are mislabeled in data from PubChem 
confirmatory assays. 
In conclusion, applied to reliable data sources from PDSP and WOMBAT databases, 
we have built validated robust and externally predictive QSAR models for 5-HT1A receptor 
ligands using kNN, RF and SVM methods. Nine false positive PubChem 5-HT1A binders 
identified by our QSAR models were further confirmed with 100% accuracy by the 
experimental test, suggesting that our models were also powerful enough to detect high noise 
to signal data sources. 
For future works, more data depositions in PubChem will be validated, for the 
purpose of identifying universally high noise-to-signal data sources, and thus improving our 
database quality by publishing our results and warning such misleading efforts. 
6.3 Summary and Future Directions of Chapter 4 
Antibiotic resistance is an escalating problem requiring the discovery of novel 
antibiotic classes acting on nonclassical cellular targets. Targeting the nonessential genes, for 
example RecA, offers possible attractive solution. In this study, we have developed 
combinatorial Quantitative Structure-Activity Relationship (QSAR) model for hundreds of 
chemically diverse RecA inhibitors and their structurally similar inactive compounds 
resulting from high-throughput screening and the subsequent confirmatory binding assays. 
The initial attempts to classify 53 RecA inhibitors out of over 3,000 non-inhibitors met with 
only limited success, due to the fact that activity cliff exists in several highly similar 
compound pairs, identified by pair-wise Tanimoto Coefficient (Tc) analysis. Then, a new 
dataset, containing 145 RecA inhibitors and 26,132 non-inhibitors, was created after both 
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data curation of those activity cliff pairs and incorporation of more up-to-date experimental 
testing results. The new dataset was clustered into three groups according to structure 
similarity, and then the variable selection kNN, RF and SVM, were employed for model 
building within each group using 2D topological Dragon chemical descriptors. Highly 
predictive QSAR models were generated and the CCRevs values were much higher than the 
CCRevs for model building without clustering. With two differently defined applicability 
domain thresholds, all validated QSAR models were employed concurrently for virtual 
screening (VS) of an in-house compound collection including 9.5 million molecules. VS 
resulted in 31 structurally unique consensus hits that were considered novel putative RecA 
inhibitors, with novel structural features that were not present in the original data set.  11 of 
in silico hits with novel scaffolds were tested experimentally and five of them were 
confirmed active against RecA, with IC50 values ranging from 5 to 28 µM. Overall, this study 
illustrates the power of the combinatorial QSAR-VS method as a general approach for the 
effective identification of structurally novel bioactive compounds.  
 For future studies, pharmacophore modeling of existing and newly discovered RecA 
inhibitors will be conducted, with hopes of optimizing the potency of current RecA inhibitors. 
Moreover, lead compounds of high interest will be tested in vivo, for their toxicity studies, as 
well as the investigation of their efficacies in animal models. 
6.4 Summary and Future Directions of Chapter 5 
The 5-Hydroxy Tryptamine receptor subtype 1A (5-HT1A) is highly expressed in the 
raphe nuclei region and limbic structures; for that reason 5-HT1A has been an attractive 
target to treat mood disorders such as anxiety and depression. Our studies demonstrated that 
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combinatorial classification QSAR models built with Dragon descriptors can accurately 
differentiate true 5-HT1A binders from non-binders. A special QSAR modeling scheme was 
employed for this imbalanced dataset and the models were rigorously validated using both 
internal (multiple training/test set divisions and Y-randomization) as well as external (five-
fold cross external validation sets) validation approaches. We have demonstrated that this 
strategy afforded multiple QSAR models with high internal and external predictive power. 
As part of our QSAR modeling workflow, the predictors were further utilized for validating 
the WOMBAT hits, with results that highly agree. On the other hand, our models used in the 
most conservative way (i.e., in consensus fashion and with the strictest applicability domain 
criteria) identified 120 putative 5-HT1A binders by virtually screened the drug-like libraries, 
GPCR-targeted libraries, and diversity libraries. After experimental validation on 
commercially available compounds, 60% of the compounds suggested by our QSAR models 
were confirmed to be 5-HT1A binders; however, it was interesting to learn that the 
experimental hit rate of the diversity library is much higher than the GPCR-targeted library, 
and the most potent 5-HT1A binder (inhibitor) was screened from the diversity library, 
sharing a very low structural similarity with its nearest neighbor compound in the modeling 
set. These interesting findings verified that model-based virtual screening outperformed the 
simple similarity search, and also challenged our conventional opinions about structure-
activity relationships (SAR), suggesting that it is not always true that more similar structures 
will lead to more similar chemical properties. Moreover, it is once again confirmed that by 
taking advantage of the various computational tools, such as QSAR modeling, more novel 
compounds could be revealed with diverse scaffolds.  
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Furthermore, as we have demonstrated in this paper, QSAR models can be 
successfully used not only to discriminate binders versus non-binders but most importantly, 
for finding promising hits by the means of virtual screening of chemical librarie
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a 
N(1) = number of inhibitors, N(2) = number of non-binders, TP = true positive (inhibitors predicted as inhibitors), FP = false positives (non-
binders predicted as inhibitors), FN = false negatives (inhibitors predicted as non-binders), TN = true negative (non-binders predicted as non-
binders), SE = sensitivity = TP/N(1), SP = specificity = TN/N(2), EN - the normalized enrichment, EN(1) = (2TP * N(2))/(TP * N(2) + FP * 
N(1)), EN(2) = (2TN * N(1))/(TN * N(1) + FN * N(2)), and CCR = correct classification rate. 
b 
Some N(1) inhibitors of and N(2) non-binders were out of application domain of all consensus models, thus having no prediction. Only data 
for compounds found within the AD were used for statistical summaries. 
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Table A1. Five-fold external cross validation test statistics for 5-HT1A binders and non-binders from PDSP 
QSAR Methods External Sets 
Prediction 
CCR 
Confusion Matrix  Statistics 
N(1)
a
 N(2)
a
 TP
a
 TN
a
 FP
a
 FN
a
  SE
a
 SP
a
 EN(1)
a
 EN(2)
a
 
 1 0.86 19
b
 14 18 11 3 2  0.90 0.79 1.62 1.77 
 2 0.61 20 13 15 6 7 5  0.75 0.46 1.16 1.30 
k-Nearest Neighbor 3 0.77 22 11 20 7 4 2  0.91 0.64 1.43 1.75 
 4 0.86 20 13 19 10 3 1  0.95 0.77 1.61 1.88 
 5 0.68 23 10 22 4 6 1  0.96 0.40 1.23 1.80 
 1 0.80 20 14 16 11 3 4  0.80 0.79 1.58 1.59 
 2 0.68 20 13 15 8 5 5  0.75 0.62 1.32 1.42 
Random Forest 3 0.84 22 11 21 8 3 1  0.95 0.73 1.56 1.88 
 4 0.74 20 13 19 7 6 1  0.95 0.54 1.35 1.83 
 5 0.83 23 10 22 7 3 1  0.96 0.70 1.52 1.88 
 1 0.87 20 14 19 11 3 1  0.95 0.79 1.63 1.88 
 2 0.68 20 13 18 6 7 2  0.90 0.46 1.25 1.64 
Support Vector Machine 3 0.95 22 11 22 10 1 0  1.00 0.91 1.83 2.00 
 4 0.76 20 13 18 8 5 2  0.90 0.62 1.40 1.72 
 5 0.76 23 10 21 6 4 2  0.91 0.60 1.39 1.75 
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Table A2.  Five-fold external cross validation test statistics for 5-HT1A binders from WOMBAT and non-binders 
from PDSP. 
QSAR Methods External Sets 
Prediction 
CCR 
Confusion Matrix  Statistics 
N(1)
a
 N(2)
a
 TP
a
 TN
a
 FP
a
 FN
a
  SE
a
 SP
a
 EN(1)
a
 EN(2)
a
 
 1 0.93 15 12 14 11 1 0  0.93 0.92 1.93 1.86 
 2 0.92 13 12 12 11 2 1  0.92 0.91 1.69 1.85 
k-Nearest Neighbor 3 0.91 15 11 15 9 2 0  1.00 0.82 1.69 2.00 
 4 0.96 13 13 13 12 1 0  1.00 0.92 1.86 2.00 
 5 0.96 13 13 13 12 1 0  1.00 0.92 1.86 2.00 
 1 0.96 15 12 15 11 1 0  1.00 0.92 1.85 2.00 
 2 0.88 13 12 12 10 2 1  0.92 0.83 1.69 1.83 
Random Forest 3 0.92 15 11 14 10 1 1  0.93 0.91 1.82 1.86 
 4 0.96 13 13 13 12 1 0  1.00 0.92 1.86 2.00 
 5 0.85 13 13 11 11 2 2  0.85 0.85 1.69 1.69 
 1 0.89 15 12 13 11 1 2  0.87 0.92 1.82 1.75 
 2 1.00 13 12 13 12 1 0  1.00 1.00 1.85 2.00 
Support Vector Machine 3 0.89 15 11 13 10 1 2  0.87 0.91 1.81 1.74 
 4 0.81 13 13 10 11 2 3  0.77 0.85 1.67 1.57 
 5 0.77 13 13 10 10 3 3  0.77 0.77 1.54 1.54 
a
 N(1) = number of inhibitors, N(2) = number of non-binders, TP = true positive (inhibitors predicted as inhibitors), FP = false positives (non-
binders predicted as inhibitors), FN = false negatives (inhibitors predicted as non-binders), TN = true negative (non-binders predicted as non-
binders), SE = sensitivity = TP/N(1), SP = specificity = TN/N(2), EN - the normalized enrichment, EN(1) = (2TP * N(2))/(TP * N(2) + FP * 
N(1)), EN(2) = (2TN * N(1))/(TN * N(1) + FN * N(2)), and CCR = correct classification rate. 
  
 
1
4
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Table A3.  Five-fold external cross validation test statistics for 5-HT1A agonists/antagonists from PubChem. 
QSAR Methods External Sets 
Prediction 
CCR 
Confusion Matrix  Statistics 
N(1)
a
 N(2)
a
 TP
a
 TN
a
 FP
a
 FN
a
  SE
a
 SP
a
 EN(1)
a
 EN(2)
a
 
 1 0.61 6 14 3 10 4 3  0.50 0.71 1.27 1.18 
 2 0.67 11 10 6 8 2 5  0.55 0.80 1.46 1.28 
k-Nearest Neighbor 3 0.72 10 11 8 7 4 2  0.80 0.64 1.38 1.52 
 4 0.55 7 13 4 7 6 3  0.57 0.54 1.11 1.11 
 5 0.43 11 10 3 6 4 8  0.27 0.60 0.81 0.90 
 1 0.46 6 14 3 6 8 3  0.50 0.43 0.93 0.92 
 2 0.57 11 10 6 6 4 5  0.55 0.60 1.15 1.13 
Random Forest 3 0.70 10 11 4 11 0 6  0.40 1.00 2.00 1.25 
 4 0.68 8 13 6 8 5 2  0.75 0.62 1.32 1.42 
 5 0.53 11 10 4 7 3 7  0.36 0.70 1.10 1.05 
a
 N(1) = number of inhibitors, N(2) = number of non-binders, TP = true positive (inhibitors predicted as inhibitors), FP = false positives (non-
binders predicted as inhibitors), FN = false negatives (inhibitors predicted as non-binders), TN = true negative (non-binders predicted as non-
binders), SE = sensitivity = TP/N(1), SP = specificity = TN/N(2), EN - the normalized enrichment, EN(1) = (2TP * N(2))/(TP * N(2) + FP * 
N(1)), EN(2) = (2TN * N(1))/(TN * N(1) + FN * N(2)), and CCR = correct classification rate. 
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Table A4. The number of screening compound within different Zcutoff 
values for 5-HT1A virtual screening. 
 
Screening Databases Number of 
Compounds 
Zcutoff Compounds 
in AD 
Compounds 
in AD (%) 
  -0.5 209 13.5% 
Prestwick 1,552 0 304 19.6% 
  0.5 458 29.5% 
  -0.5 1334 2.5% 
World Drug Index 53,382 0 3295 6.2% 
  0.5 7371 13.8% 
  -0.5 31 1.3% 
TimTec GPCRTargeted Library 2,300 0 151 6.6% 
  0.5 542 23.6% 
  -0.5 144 4.5% 
Asinex GPCR Targeted Library 3,233 0 890 27.5% 
  0.5 2279 70.5% 
  -0.5 46 0.5% 
TimTec Diversity Library 10,000 0 222 2.2% 
  0.5 803 8.0% 
  -0.5 39 0.8% 
Asinex Diversity Library 5,072 0 267 5.3% 
  0.5 811 16.0% 
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